#### Factor IX

30

## 19. GlycoPEGylation of Factor IX produced in CHO cells

This example sets forth the preparation of asialoFactor IX and its sialylation with CMP-sialic acid-PEG.

Desialylation of rFactor IX. A recombinant form of Coagulation Factor IX (rFactor 5 IX ) was made in CHO cells. 6000 IU of rFactor IX were dissolved in a total of 12 mL USP H2O. This solution was transferred to a Centricon Plus 20, PL-10 centrifugal filter with another 6 mL USP H2O. The solution was concentrated to 2 mL and then diluted with 15 mL 50~mM Tris-HCl pH 7.4, 0.15 M NaCl, 5 mM CaCl<sub>2</sub>, 0.05% NaN<sub>3</sub> and then reconcentrated. The dilution/concentration was repeated 4 times to effectively change the buffer to a final 10 volume of 3.0 mL. Of this solution, 2.9 mL (about 29 mg of rFactor IX) was transferred to a small plastic tube and to it was added 530 mU o2-3,6,8-Neuraminidase-agarose conjugate (Vibrio cholerae, Calbiochem, 450 µL). The reaction mixture was rotated gently for 26.5 hours at 32 °C. The mixture was centrifuged 2 minutes at 10,000 rpm and the supernatant was collected. The agarose beads (containing neuraminidase) were washed 6 times with 0.5 15 mL 50 mM Tris-HCl pH 7.12, 1 M NaCl, 0.05% NaN3. The pooled washings and supernatants were centrifuged again for 2 minutes at 10,000 rpm to remove any residual agarose resin. The pooled, desialylated protein solution was diluted to 19 mL with the same buffer and concentrated down to ~2 mL in a Centricon Plus 20 PL-10 centrifugal filter. The solution was twice diluted with 15 mL of 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 0.05% 20 NaN3 and reconcentrated to 2 mL. The final desialyated rFactor IX solution was diluted to 3 mL final volume (~10 mg/mL) with the Tris Buffer. Native and desialylated rFactor IX samples were analyzed by IEF-Electrophoresis. Isoelectric Focusing Gels (pH 3-7) were run using 1.5  $\mu$ L (15  $\mu$ g) samples first diluted with 10  $\mu$ L Tris buffer and mixed with 12  $\mu$ L sample loading buffer. Gels were loaded, run and fixed using standard procedures. Gels 25 were stained with Colloidal Blue Stain (Figure 154), showing a band for desialylated Factor IX.

Preparation of PEG (1 kDa and 10 kDa)-SA-Factor IX. Desialylated rFactor-IX (29 mg, 3 mL) was divided into two 1.5 mL (14.5 mg) samples in two 15 mL centrifuge tubes. Each solution was diluted with 12.67 mL 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 0.05% NaN<sub>1</sub> and either CMP-SA-PEG-1k or 10k (7.25 µmol) was added. The tubes were

inverted gently to mix and 2.9 U ST3Gal3 (326  $\mu$ L) was added (total volume 14.5 mL). The tubes were inverted again and rotated gently for 65 hours at 32 °C. The reactions were stopped by freezing at –20 °C. 10  $\mu$ g samples of the reactions were analyzed by SDS-PAGE. The PEGylated proteins were purified on a Toso Haas Biosep G3000SW (21.5 x 30 cm, 13 um) HPLC column with Dulbecco's Phosphate Buffered Saline, pH 7.1 (Gibco), 6 mL/min. The reaction and purification were monitored using SDS Page and IEF gels. Novex Tris-Glycine 4-20% 1 mm gels were loaded with 10  $\mu$ L (10  $\mu$ g) of samples after dilution with 2  $\mu$ L of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% NaN3 buffer and mixing with 12  $\mu$ L sample loading buffer and 1  $\mu$ L 0.5 M DTT and heated for 6 minutes at 85 °C. Gels were stained with Colloidal Blue Stain (Figure 155) showing a band for PEG (1 kDa and 10 kDa)-SA-Factor IX.

5

10

15

25

## Direct Sialyl-GlycoPEGylation of Factor IX

This example sets forth the preparation of sialyl-PEGylation of Factor IX without prior sialidase treatment.

Sialyl-PEGylation of Factor-IX with CMP-SA-PEG-(10 KDa). Factor IX (1100 IU), which was expressed in CHO cells and was fully sialylated, was dissolved in 5 mL of 20 mM histidine, 520 mM glycine, 2% sucrose, 0.05% NaN<sub>3</sub> and 0.01% polysorbate 80, pH 5.0.

The CMP-SA-PEG-(10 kDa) (27 mg, 2.5 μmol) was then dissolved in the solution and 1 U of ST3Gal3 was added. The reaction was complete after gently mixing for 28 hours at 32°C.

The reaction was analyzed by SDS-PAGE as described by Invitrogen. The product protein was purified on an Amersham Superdex 200 (10 x 300 mm, 13 μm) HPLC column with phosphate buffered saline, pH 7.0 (PBS), 1 mL/min. R<sub>t</sub> = 9.5 min.

Statyl-PEGylation of Factor-IX with CMP-SA-PEG-(20 kDa). Factor IX (1100 IU), which was expressed in CHO cells and was fully statylated, was dissolved in 5 mL of 20 mM histidine, 520 mM glycine, 2% sucrose, 0.05% NaN<sub>3</sub> and 0.01% polysorbate 80, pH 5.0. The CMP-SA-PEG-(20 kDa) (50 mg, 2.3 µmol) was then dissolved in the solution and CST-II was added. The reaction mixture was complete after gently mixing for 42 hours at 32°C. The reaction was analyzed by SDS-PAGE as described by Invitrogen.

The product protein was purified on an Amersham Superdex 200 ( $10 \times 300$  mm, 13  $\mu m$ ) HPLC column with phosphate buffered saline, pH 7.0 (Fisher), 1 mL/min.  $R_t = 8.6$  min.

## 21. Sialic Acid Capping of GlycoPEGylated Factor IX

This examples sets forth the procedure for sialic acid capping of sialylglycoPEGylated peptides. Here, Factor-IX is the exemplary peptide.

Sialic acid capping of N-linked and O-linked Glycans of Factor-IX-SA-PEG (10 kDa). Purified r-Factor-IX-PEG (10 kDa) (2.4 mg) was concentrated in a Centricon<sup>®</sup> Plus 20 PL-10 (Millipore Corp., Bedford, MA) centrifugal filter and the buffer was changed to 50 mM Tris-HCl pH 7.2, 0.15 M NaCl, 0.05% NaN<sub>3</sub> to a final volume of 1.85 mL. The protein solution was diluted with 372 µL of the same Tris buffer and 7.4 mg CMP-SA (12 µmol) was added as a solid. The solution was inverted gently to mix and 0.1 U ST3Gal3 were added. The reaction mixture was rotated gently for 42 hours at 32 °C.

A 10  $\mu$ g sample of the reaction was analyzed by SDS-PAGE. Novex Tris-Glycine 4-12% 1 mm gels were performed and stained using Colloidal Blue as described by Invitrogen. Briefly, samples, 10  $\mu$ L (10  $\mu$ g), were mixed with 12  $\mu$ L sample loading buffer and 1  $\mu$ L 0.5 M DTT and heated for 6 minutes at 85 °C (Figure 156, lane 4).

#### Factor VIIa

5

10

15

20

25

30

22. GlycoPEGylation of Recombinant Factor VIIa produced in BHK cells

This example sets forth the PEGylation of recombinant Factor VIIa made in BHK cells.

Preparation of Asialo-Factor VIIa. Recombinant Factor VIIa was produced in BHK cells (baby hamster kidney cells). Factor VIIa (14.2 mg) was dissolved at 1 mg/ml in buffer solution (pH 7.4, 0.05 M Tris, 0.15 M NaCl, 0.001 M CaCl<sub>2</sub>, 0.05% NaN<sub>3</sub>) and was incubated with 300 mU/mL sialidase (Vibrio cholera)-agarose conjugate for 3 days at 32 °C. To monitor the reaction a small aliquot of the reaction was diluted with the appropriate buffer and an IEF gel performed according to Invitrogen procedures (Figure 157). The mixture was centrifuged at 3,500 rpm and the supernatant was collected. The resin was washed three times (3×2 mL) with the above buffer solution (pH 7.4, 0.05 M Tris, 0.15 M NaCl, 0.05% NaN<sub>3</sub>) and the combined washes were concentrated in a Centricon-Plus-20. The remaining

solution was buffer exchanged with 0.05 M Tris (pH 7.4), 0.15 M NaCl, 0.05% NaN<sub>3</sub> to a final volume of 14.4 mL.

Preparation of Factor VIIa-SA-PEG (1 kDa and 10 kDa). The desialylation rFactor VIIa solution was split into two equal 7.2 ml samples. To each sample was added either CMP-SA-5-PEG(1 kDa) (7.4 mg) or CMP-SA-5-PEG(10 kDa) (7.4 mg). ST3Gal3 (1.58U) was added to both tubes and the reaction mixtures were incubated at 32°C for 96 hrs. The reaction was monitored by SDS-PAGE gel using reagents and conditions described by Invitrogen. When the reaction was complete, the reaction mixture was purified using a Toso Haas TSK-Gel-3000 preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The combined fractions containing the product were concentrated at 4°C in Centricon-Plus-20 centrifugal filters (Millipore, Bedford, MA) and the concentrated solution reformulated to yield 1.97 mg (bicinchoninic acid protein assay, BCA assay, Sigma-Aldrich, St. Louis MO) of Factor VIIa-PEG. The product of the reaction was analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples were dialyzed against water and analyzed by MALDI-TOF. Figure 158 shows the MALDI results for native Factor VIIa. Figure 159 contains the MALDI results for Factor VIIa PEGylated with 1 kDa PEG where peak of Factor VIIa PEGylated with 1KDa PEG is evident. Figure 160 contains the MALDI results for Factor VIIa PEGylated with 10 kDa PEG where a peak for Factor VIIa PEGylated with 10 kDa PEG is evident. Figure 161 depicts the SDS-PAGE analysis of all of the reaction products, where a band for Factor VIIa-SA-PEG (10 kDa) is evident.

## Follicle Stimulating Hormone (FSH)

10

15

20

25

30

## 23. GlycoPEGylation of human pituitary-derived FSH

This example illustrates the assembly of a conjugate of the invention. Follicle Stimulating Hormone (FSH) is desialylated and then conjugated with CMP-(sialic acid)-PEG.

Desialylation of Follicle Stimulating Hormone. Follicle Stimulating Hormone (FSH) (Human Pituitary, Calbiochem Cat No. 869001), 1 mg, was dissolved in 500 μL 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 5 mM CaCl<sub>2</sub>. This solution, 375 μL, was transferred to a small plastic tube and to it was added 263 mU Neuraminidase II (*Vibrio cholerae*). The reaction mixture was shaken gently for 15 hours at 32 °C. The reaction mixture was added to

N-(p-aminophenyl)oxamic acid-agarose conjugate, 600  $\mu$ L, pre-equilibrated with 50 mM Tris-HCl pH 7.4, 150 mM NaCl and 0.05% NaN<sub>3</sub> and gently rotated 6.5 hours at 4 °C. The suspension was centrifuged for 2 minutes at 14,000 rpm and the supernatant was collected. The beads were washed 5 times with 0.5 mL of the buffer and all supernatants were pooled. The enzyme solution was dialyzed (7000 MWCO) for 15 hours at 4 °C with 2 L of a solution containing 50 mM Tris –HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub>, and then twice for 4 hours at 4 °C into 50 mM Tris –HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub>. The solution was concentrated to 2  $\mu$ g/ $\mu$ L by Speed Vac and stored at –20 °C. Reaction samples were analyzed by IEF gels (pH 3-7) (Invitrogen) (Figure 162).

Preparation of human pituitary-derived SA-FSH and PEG-SA-Follicle Stimulating Hormone. Desialylated FSH (100  $\mu$ g, 50  $\mu$ L) and CMP-sialic acid or CMP-SA-PEG (1 kDa or 10 kDa) (0.05 umol) were dissolved in 13.5  $\mu$ L H<sub>2</sub>O (adjusted to pH 8 with NaOH) in 0.5 mL plastic tubes. The tubes were vortexed briefly and 40 mU ST3Gal3 (36.5  $\mu$ L) was added (total volume 100  $\mu$ L). The tubes were vortexed again and shaken gently for 24 hours at 32 °C. The reactions were stopped by freezing at -80 °C. Reaction samples of 15  $\mu$ g were analyzed by SDS-PAGE (Figure 163), IEF gels (Figure 164) and MALDI-TOF. Native FSH was also analyzed by SDS-PAGE (Figure 165)

10

15

2.0

25

Analysis of SDS PAGE and IEF Gels of Reaction Products. Novex Tris-Glycine 8-16% 1 mm gels for SDS PAGE analysis were purchased from Invitrogen. 7.5  $\mu$ L (15  $\mu$ g) of FSH reaction samples were diluted with 5  $\mu$ L of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% NaN<sub>3</sub> buffer, mixed with 15  $\mu$ L sample loading buffer and 1  $\mu$ L 9 M  $\mu$ -mercaptoethanol and heated for 6 minutes at 85 °C. Gels were run as directed by Invitrogen and stained with Colloidal Blue Stain (Invitrogen).

FSH samples (15  $\mu$ g) were diluted with 5  $\mu$ L Tris buffer and mixed with 15  $\mu$ L sample loading buffer (Figure 162). The samples were then applied to Isoelectric Focusing Gels (pH 3-7) (Invitrogen) (Figure 165). Gels were run and fixed as directed by Invitrogen and then stained with Colloidal Blue Stain.

<u>24. GlycoPEGylation of recombinant FSH produced recombinantly in CHO</u> cells

This example illustrates the assembly of a conjugate of the invention. Desialylated FSH was conjugated with CMP-(sialic acid)-PEG.

5

10

15

20

25

30

Preparation of recombinant Asialo-Follicle Stimulation Hormone. Recombinant Follicle Stimulation Hormone (rFSH) produced from CHO was used in these studies. The 7,500 IU of rFSH was dissolved in 8 mL of water. The FSH solution was dialyzed in 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 5 mM CaCl<sub>2</sub> and concentrated to 500 μL in a Centricon Plus 20 centrifugal filter. A portion of this solution (400 μL) (~0.8 mg FSH) was transferred to a small plastic tube and to it was added 275 mU Neuraminidase II (Vibrio cholerae). The reaction mixture was mixed for 16 hours at 32 °C. The reaction mixture was added to prewashed N-(p-aminophenyl)oxamic acid-agarose conjugate (800 μL) and gently rotated for 24 hours at 4 °C. The mixture was centrifuged at 10,000 rpm and the supernatant was collected. The beads were washed 3 times with 0.6 mL Tris-EDTA buffer, once with 0.4 mL Tris-EDTA buffer and once with 0.2 mL of the Tris-EDTA buffer and all supernatants were pooled. The supernatant was dialyzed at 4 °C against 2 L of 50 mM Tris –HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub> and then twice more against 50 mM Tris –HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub>. The dialyzed solution was then concentrated to 420 μL in a Centricon Plus 20 centrifugal filter and stored at ~20 °C.

Native and desialylated rFSH samples were analyzed by SDS-PAGE and IEF (Figure 166). Novex Tris-Glycine 8-16% 1 mm gels were purchased from Invitrogen. Samples (7.5  $\mu L$ , 15  $\mu g$ ) samples were diluted with 5  $\mu L$  of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% NaN3 buffer, mixed with 15  $\mu L$  sample loading buffer and 1  $\mu L$  9 M  $\beta$ -mercaptoethanol and heated for 6 minutes at 85 °C. Gels were run as directed by Invitrogen and stained with Colloidal Blue Stain (Invitrogen). Isoelectric Focusing Gels (pH 3-7) were purchased from Invitrogen. Samples (7.5  $\mu L$ , 15  $\mu g$ ) were diluted with 5  $\mu L$  Tris buffer and mixed with 15  $\mu L$  sample loading buffer. Gels were loaded, run and fixed as directed by Invitrogen. Gels were stained with Colloidal Blue Stain. Samples of native and desialylated FSH were also dialyzed against water and analyzed by MALDI-TOF.

Sialyl-PEGylation of recombinant Follicle Stimulation Hormone. Desialylated FSH (100 µg, 54 µL) and CMP-SA-PEG (1 kDa or 10 kDa) (0.05 µmol) were dissolved in 28

 $\mu$ L 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN<sub>3</sub>, pH 7.2 in 0.5 mL plastic tubes. The tubes were vortexed briefly and 20 mU of ST3Gal3 was added (total volume 100  $\mu$ L). The tubes were vortexed again, mixed gently for 24 hours at 32 °C and the reactions stopped by freezing at -80 °C. Samples of this reaction were analyzed as described above by SDS-PAGE gels (Figure 167), IEF gels (Figure 168) and MALDI-TOF MS.

MALDI was also performed on the PEGylated rFSH. During ionization, SA-PEG is eliminated from the N-glycan structure of the glycoprotein. Native FSH gave a peak at 13928; AS-rFSH (13282); resialylated r-FSH (13332); PEG1000-rFSH (13515; 14960 (1); 16455 (2); 17796 (3); 19321 (4)); and PEG 10000 (23560 (1); 34790 (2); 45670 (3); and 56760 (4)).

## 25. Pharmacokinetic Study of GlycoPEGylated FSH

This example sets forth the *in vivo* testing of the pharmacokinetic properties glycoPEGylated Follicle Stimulating Hormone (FSH) prepared according to the methods of the invention as compared to non-PEGylated FSH.

FSH, FSH-SA-PEG (1 kDa) and FSH-SA-PEG (10 kDa) were radioiodinated using standard conditions (Amersham Biosciences, Arlington Heights, IL) and formulated in phosphate buffered saline containing 0.1% BSA. After dilution in phosphate buffer to the appropriate concentration, each of the test FSH proteins (0.4 µg, each) was injected intraveneously into female Sprague Dawley rats (250-300 g body weight) and blood drawn at time points from 0 to 80 hours. Radioactivity in blood samples was analyzed using a gamma counter and the pharmacokinetics analyzed using standard methods (Figure 169). FSH was cleared from the blood much more quickly than FSH-PEG(1 kDa), which in turn was clear somewhat more quickly than FSH-PEG(10 kDa).

25

30

20

10

15

## 26. Sertoli Cell Bioassay for In Vitro Activity of GlycoPEGylated FSH

This example sets forth a bioassay for follicle stimulating hormone (FSH) activity based on cultured Sertoli cells. This assay is useful to determine the bioactivity of FSH after glycan remodeling, including glycoconjugation.

This bioassay is based on the dose-response relationship that exists between the amount of estradiol produced when FSH, but not lutenizing hormone (LH), is added to

cultured Sertoli cells obtained from immature old rats. Exogenous testosterone is converted to  $17\beta$ -estradiol in the presence of FSH.

Seven to 10 days old Sprague-Dawley rats were used to obtain Sertoli cells. After sacrifice, testes were decapsulated and tissue was dispersed by incubation in collagenase (1 mg/ml), trypsin (1mg/ml), hyaluronidase (1 mg/ml) and DNases (5 µg/ml) for 5 to 10 min. The tubule fragments settled to the bottom of the flask and were washed in PBS (1x). The tubule fragments were reincubated for 20 min with a media containing the same enzymes: collagenase (1 mg/ml), trypsin (1mg/ml), hyaluronidase (1 mg/ml) and DNases (5 µg/ml).

5

10

15

20

25

30

The tubule fragments were homogenized and plated into a 24 well plate in a serum free media.  $5 \times 10^3$  cells were dispersed per well. After 48h incubation at  $37^\circ$  C and 5% CO<sub>2</sub>, fresh media was added to the cells. Composition of the serum free media: DMEM (1 vol), Ham's F10 nutrient mixture (1 vol), insulin 1 µg/ml, Transferrin 5 µg/ml, EGF 10 ng/ml, T4 20 pg/ml, Hydrocortisone  $10^{-8}$  M, Retinoic acid  $10^{-6}$  M.

The stimulation experiment consists of a 24 hour incubation with standard FSH or samples at 37°C and 5% CO<sub>2</sub>. The mean intra-assay coefficient of variation is 9% and the mean inter-assay coefficient of variation is 11%.

The 17B-estradiol Elisa Kit DE2000 (R&D Systems, Minneapolis, MN) was used to quantify the level of estradiol after incubation with FSH, FSH-SA-PEG (1 kDa) and FSH-SA-PEG (10 kDa).

The procedure was as follows: 100  $\mu$ l of Estradiol Standard (provided with kit and prepared as per instructions with kit) or sample was pipetted into wells of 17B-estradiol Elisa plate(s); 50  $\mu$ l of 17B-estradiol Conjugate (provided with kit, prepared as per instructions with kit) was added to each well; 50  $\mu$ l of 17B-estradiol antibody solution (provided with kit and prepared as per instructions with kit) was added to each well; plates were incubated for 2 hour at room temperature at 200 rpm; the liquid was aspirated from each well; the wells were washed 4 times using the washing solution; all the liquid was removed from the wells; 200  $\mu$ l of pNPP Substrate (provided with kit and prepared as per instructions with kit) was added to all wells and incubated for 45 min; 50  $\mu$ l of Stop solution (provided with kit and prepared as per instructions with kit) was added and the plates were read it at 405 nm (Figure 170). While FSH-PEG(10 kDa) exhibited a modest stimulation of Sertoli cells, at 1  $\mu$ g/ml, FSH-PEG(1 kDa) stimulated Sertoli cells up to 50% more than unPEGylated FSH.

## 27. Steelman-Pohley Bioassay of In Vivo Activity of GlycoPEGylated FSH

In this example, the Steelman-Pohley bioassay (Steelman and Pohley, 1953, Endocrinology 53:604-615) was used to determine the *in vivo* activity of glycoPEGylated FSH. The Steelman-Pohley assay uses the change in ovary weight of a rat to measure the *in vivo* activity of FSH that is coiniected with human chorionic gonadotropin.

5

10

15

20

25

The Steelman-Pohley bioassay was performed according to the protocol described in Christin-Maitre et al. (2000, Methods 21:51-57). Seventy female Sprague-Dawley Rats (Charles River Laboratories, Wilmington, MA), aged 21 to 22 days, were housed in the testing facility for at least 5 days before the beginning the assay procedure. Throughout the procedure, the animal room was climate controlled at 18 to 26°C, 30 to 70% relative humidity, and 12 hr. artificial light/12 hr. dark. All animals were fed Certified Rodent Chow (Harlan Teklad, Madison WI) or the equivalent, and water, both ad libitum. Animal procedures were performed at Calvert Preclinical Services, Inc. (Olyphant, PA).

Recombinant FSH was expressed in CHO cells, purified by standard techniques and glycoPEGylated with PEG (1 kDa). The rats were divided into seven test groups, with ten animals per group. On days –1 and 0, animals of all groups were subcutaneously injected with 20 I.U. of human chorionic gonadotropin (HCG) in 0.5 ml of 0.9 % NaCl. On days 1, 2 and 3, the control animals were subcutaneously injected with a dose of 0.5 ml containing 20 I.U. HCG in 0.9% NaCl, while in the other groups, the HCG dose was augmented with either rFSH or rFSH-SA-PEG (1 kDa) at either 0.14 µg, 0.4 µg or 1.2 µg per dose. On day 4, the animals were euthanized by CO2 inhalation. The ovaries were removed, trimmed and weighted. The average ovary weight was determined for each group.

Figure 171 presents the average ovary weight of the test groups on day 4. The groups receiving HCG alone (control) or the low dose (0.14 µg) of either rFSH or rFSH-SA-PEG (1 kDa) had ovary weights that were roughly equivalent. The groups receiving the medium (0.4 µg) or high (1.2 µg) doses of rFSH or rFSH-SA-PEG (1 kDa) had ovary weights roughly twice that of the control group. At the medium dose (0.4 µg), the glycoPEGylated rFSH had roughly the same in vivo activity (as determined by ovary weight) as the unPEGylated rFSH.

At the high dose (1.2 µg), the glycoPEGylated rFSH had somewhat higher in vivo activity than the unPEGylated rFSH.

#### G-CSF

5

10

15

20

25

30

# 28. GlycoPEGylation of G-CSF produced in CHO cells

Preparation of Asialo-Granulocyte-Colony Stimulation Factor (G-CSF). G-CSF produced in CHO cells is dissolved at 2.5 mg/mL in 50 mM Tris 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 5 mM CaCl2 and concentrated to 500 µL in a Centricon Plus 20 centrifugal filter. The solution is incubated with 300 mU/mL Neuraminidase II (Vibrio cholerae) for 16 hours at 32 °C. To monitor the reaction a small aliquot of the reaction is diluted with the appropriate buffer and a IEF gel performed. The reaction mixture is then added to prewashed N-(p-aminophenyl)oxamic acid-agarose conjugate (800 μL/mL reaction volume) and the washed beads gently rotated for 24 hours at 4 °C. The mixture is centrifuged at 10,000 rpm and the supernatant was collected. The beads are washed 3 times with Tris-EDTA buffer, once with 0.4 mL Tris-EDTA buffer and once with 0.2 mL of the Tris-EDTA buffer and all supernatants are pooled. The supernatant is dialyzed at 4 °C against 50 mM Tris -HCl pH 7.4. 1 M NaCl, 0.05% NaN3 and then twice more against 50 mM Tris -HCl pH 7.4, 1 M NaCl. 0.05% NaN3. The dialyzed solution is then concentrated using a Centricon Plus 20 centrifugal filter and stored at -20 °C. The conditions for the IEF gel were run according to the procedures and reagents provided by Invitrogen. Samples of native and desialylated G-CSF are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of G-CSF-(alpha2,3)-Sialyl-PEG. Desialylated G-CSF was dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN3, pH 7.2. The solution is incubated with 1 mM CMP-sialic acid-PEG and 0.1 U/mL of ST3Gall at 32°C for 2 days. To monitor the incorporation of sialic acid-PEG, a small aliquot of the reaction had CMP-SA-PEG-fluorescent ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The fluorescent label incorporation into the peptide is quantitated using an in-line fluorescent detector. After 2 days, the reaction mixture is purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis

according to the procedures and reagents supplied by Invitrogen. Samples of native and PEGylated G-CSF are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of G-CSF-(alpha2,8)-Sialyl-PEG. G-CSF produced in CHO cells, which contains an alpha2,3-sialylated O-linked glycan, is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 1 mM CMP-sialic acid-PEG and 0.1 U/mL of CST-II at 32°C for 2 days. To monitor the incorporation of sialic acid-PEG, a small aliquot of the reaction has CMP-SA-PEG-fluorescent ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The fluorescent label incorporation into the peptide is quantitated using an in-line fluorescent detector. After 2 days, the reaction mixture is purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples of native and PEGylated G-CSF are dialyzed against water and analyzed by MALDI-TOF MS.

10

15

20

25

30

Preparation of G-CSF-(alpha2,6)-Sialyl-PEG. G-CSF, containing only O-linked GalNAc, is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 1 mM CMP-sialic acid-PEG and 0.1 U/mL of ST6GalNAcl or II at 32°C for 2 days. To monitor the incorporation of sialic acid-PEG, a small aliquot of the reaction has CMP-SA-PEG-fluorescent ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The fluorescent label incorporation into the peptide is quantitated using an in-line fluorescent detector. After 2 days, the reaction mixture is purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples of native and PEGylated G-CSF are dialyzed against water and analyzed by MALDI-TOF MS.

G-CSF produced in CHO cells was treated with Arthrobacter sialidase and was then purified by size exclusion on Superdex75 and was treated with ST3Gal1 or ST3 Gal2 and then with CMP-SA-PEG 20Kda. The resulting molecule was purified by ion exchange and

gel filtration and analysis by SDS PAGE demonstrated that the PEGylation was complete.

This is the first demonstration of glycoPEGylation of an O-linked glycan.

#### Glucocerebrosidase

5

10

15

20

25

30

29. Glucocerebrosidase-mannose-6-phosphate produced in CHO cells

This example sets forth the procedure to glycoconjugate mannose-6-phosphate to a peptide produced in CHO cells such as glucocerebrosidase.

Preparation of asialo-glucoceramidase. Glucocerebrosidase produced in CHO cells is dissolved at 2.5 mg/mL in 50 mM Tris 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, and is incubated with 300 mU/mL sialidase-agarose conjugate for 16 hours at 32 °C. To monitor the reaction a small aliquot of the reaction is diluted with the appropriate buffer and a IEF gel and SDS-PAGE performed according to Invitrogen procedures. The mixture is centrifuged at 10,000 rpm and the supernatant is collected. The beads are washed 3 times with Tris-EDTA buffer, once with 0.4 mL Tris-EDTA buffer, and once with 0.2 mL of the Tris-EDTA buffer. All supernatants are pooled. The supernatant is dialyzed at 4 °C against 50 mM Tris-HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub> and then twice more against 50 mM Tris-HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub>. The dialyzed solution is then concentrated using a Centricon Plus 20 centrifugal filter. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of Glucocerebrosidase-SA-linker-Mannose-6-phosphate (procedure 1). Asialo-glucocerebrosidasefrom above is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN3, pH 7.2. The solution is incubated with 1 mM CMP-sialic acid-linker-Man-6-phosphate and 0.1 U/mL of ST3Gal3 at 32°C for 2 days. To monitor the incorporation of sialic acid-linker-Man-6-phosphate, a small aliquot of the reaction had CMP-SA-PEG-fluorescent ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas TSK-Gel-3000 analytical column using PBS buffer (pH 7.1). The fluorescent label incorporation into the peptide is quantitated using an in-line fluorescent detector. When the reaction is complete, the reaction mixture is purified using a Toso Haas TSK-Gel-3000 preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using

SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of Glucocerebrosidase-SA-linker-Mannose-6-phosphate (procedure 2). Glucocerebrosidase, produced in CHO but incompletely sialylated, is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 1 mM CMP-sialic acid-linker-Man-6-phosphate and 0.1 U/mL of ST3Gal3 at 32°C for 2 days. To monitor the incorporation of sialic acid-linker-Man-6-phosphate, a small aliquot of the reaction had CMP-SA-PEG-fluorescent ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas TSK-Gel-3000 analytical column using PBS buffer (pH 7.1). The fluorescent label incorporation into the peptide is quantitated using an in-line fluorescent detector. When the reaction is complete, the reaction mixture is purified using a Toso Haas TSK-Gel-3000 preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

## 30. Glucocerebrosidase-transferrin

10

15

20

25

30

This example sets forth the procedures for the glycoconjugation of proteins, and in particular, transferrin is glycoconjugated to glucocerebrosidase. The GleNAc-ASN structures are created on glucoceraminidase, and Transferrin-SA-Linker-Gal-UDP is conjugated to GNDF GleNAc-ASN structures using galactosyltransferase.

Preparation of GleNAc-glucocerebrosidase (Cerezyme<sup>TM</sup>). Cerezyme<sup>TM</sup> (glucocerebrosidase) produced in CHO cells is dissolved at 2.5 mg/mL in 50 mM Tris 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, and is incubated with 300 mU/mL Endo-H-agarose conjugate for 16 hours at 32 °C. To monitor the reaction a small aliquot of the reaction is diluted with the appropriate buffer and a IEF gel and SDS-PAGE performed according to Invitrogen procedures. The mixture is centrifuged at 10,000 rpm and the supernatant is collected. The beads are washed 3 times with Tris-EDTA buffer, once with 0.4 mL Tris-EDTA buffer and once with 0.2 mL of the Tris-EDTA buffer and all supernatants are pooled. The supernatant is dialyzed at 4 °C against 50 mM Tris −HCl pH 7.4, 1 M NaCl, 0.05% NaN₃ and then twice

more against 50 mM Tris –HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub>. The dialyzed solution is then concentrated using a Centricon Plus 20 centrifugal filter. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of Transferrin-SA-Linker-Gal-glucocerebrosidase. Transferrin-SA-Linker-Gal-UDP from above is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 5 mM MnCl<sub>2</sub>, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 2.5 mg/mL GleNAc-glucocerebrosidaseand 0.1 U/mL of galactosyltransferase at 32°C for 2 days. To monitor the incorporation of glucocerebrosidase, the peptide is separated by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1) and the product detected by UV absorption. The reaction mixture is then purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

#### GM-CSF

5

10

15

20

25

30

31. Generation and PEGylation of GlcNAc-ASN Structures: GM-CSF produced in Saccharomyces

This example sets forth the preparation of Tissue-type Activator with PEGylated GicNAc-Asn structures.

Recombinant GM-CSF expressed in yeast is expected to contain 2 N-linked and 2 O-linked glycans. The N-linked glycans should be of the branched mannan type. This recombinant glycoprotein is treated with an endoglycosidase from the group consisting of endoglycosidase H, endoglycosidase-F1, endoglycosidase-F2, endoglycosidase-F3, endoglycosidase-M either alone or in combination with mannosidases I, II and III to generate GlcNAc nubs on the asparagine (Asn) residues on the peptide/protein backbone.

The GlcNAc-Asn structures on the peptide/protein backbone is then be modified with galactose or galactose-PEG using UDP-galactose or UDP-galactose-6-PEG, respectively, and a galactosyltransferase such as GalT1. In one case the galactose-PEG is the terminal residue.

In the second case the galactose is further modified with SA-PEG using a CMP-SA-PEG donor and a sialyltransferase such as ST3GalIII. In another embodiment the GlcNAc-Asn structures on the peptide/protein backbone can be galactosylated and sialylated as described above, and then further sialylated using CMP-SA-PEG and an  $\alpha$ 2,8-sialyltransferase such as the enzyme encoded by the *Campylobacter jejuni* cst-II gene.

#### Herceptin™

5

10

25

# 32. Glycoconjugation of mithramycin to Herceptin™

This example sets forth the procedures to glycoconjugate a small molecule, such as mithramycin to Fe region glycans of an antibody molecule produced in mammalian cells. Here, the antibody Herceptin<sup>TM</sup> is used, but one of skill in the art will appreciate that the method can be used with many other antibodies.

Preparation of Herceptin™-Gal-linker-mithramycin. Herceptin™ is dissolved at

2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 5 mM MnCl<sub>2</sub>, 0.05% NaN<sub>3</sub>, pH 7.2. The

solution is incubated with 1 mM UDP-galactose-linker-mithramycin and 0.1 U/mL of
galactosyltransferase at 32°C for 2 days to introduce the mithramycin in the Fc region
glycans. To monitor the incorporation of galactose, a small aliquot of the reaction has ¹⁴Cgalactose-UDP ligand added; the label incorporated into the peptide is separated from the free
label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH

7.1). The radioactive label incorporation into the peptide is quantitated using an in-line
radiation detector.

When the reaction is complete, the reaction mixture is purified using a Toso Haas TSK-Gel-3000 preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The fractions containing product are combined, concentrated, buffer exchanged and then freeze-dried. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

#### Interferon a and Interferon B

5

10

15

20

25

30

33. GlycoPEGylation of Proteins expressed in Mammalian or Insect Systems: EPO, Interferon  $\alpha$  and Interferon  $\beta$ 

This example sets forth the preparation of PEGylated peptides that are expressed in mammalian and insect systems.

Preparation of acceptor from mammalian expression systems. The peptides to be glycoPEGylated using CMP-sialic acid PEG need to have glycans terminating in galactose. Most peptides from mammalian expression systems will have terminal sialic acid that first needs to be removed.

Sialidase digestion. The peptide is desialylated using a sialidase. A typical procedure involves incubating a 1 mg/mL solution of the peptide in Tris-buffered saline, pH 7.2, with 5 mM CaCl<sub>2</sub> added, with 0.2 U/mL immobilized sialidase from Vibrio cholera (Calbiochem) at 32°C for 24 hours. Microbial growth can be halted either by sterile filtration or the inclusion of 0.02% sodium azide. The resin is then removed by centrifugation or filtration, and then washed to recover entrapped peptide. At this point, EDTA may be added to the solution to inhibit any sialidase that has leached from the resin.

Preparation from insect expression systems. EPO, interferon-alpha, and interferon-beta may also be expressed in non-mammalian systems such as yeast, plants, or insect cells. The peptides to be glycoPEGylated using CMP-sialic acid PEG need to have glycans terminating in galactose. The majority of the N-glycans on peptides expressed in insect cells, for example, are the trimannosyl core. These glycans are first built out to glycans terminating in galactose before they are acceptors for sialyltransferase.

Building acceptor glycans from trimannosyl core. Peptide (1 mg/mL) in Trisbuffered saline, pH 7.2, containing 5 mM MnCl<sub>2</sub>, 5 mM UDP-gleNAc, 0.05 U/mL GLCNACT I, 0.05 U/mL GLCNACT II, is incubated at 32°C for 24 hours or until the reaction is substantially complete. Microbial growth can be halted either by sterile filtration or the inclusion of 0.02% sodium azide. After buffer exchange to remove UDP and other small molecules, UDP-galactose and MnCl<sub>2</sub> are each added to 5 mM, galactosyltransferase is added to 0.05 U/mL, and is incubated at 32°C for 24H or until the reaction is substantially

complete. Microbial growth can be halted either by sterile filtration or the inclusion of 0.02% sodium azide. The peptides are then ready for glycoPEGylation.

Building O-linked glycans. A similar strategy may be employed for interferon alpha to produce enzymatically the desired O-glycan Gal-GalNAc. If necessary, GalNAc linked to serine or threonine can be added to the peptide using appropriate peptide GalNAc transferases (e.g. GalNAc T1, GalNAc T2, T3, T4, etc.) and UDP-GalNAc. Also, if needed, galactose can be added using galactosyltransferase and UDP-galactose.

GlycoPEGylation using sialyltransferase. The glycopeptides (1 mg/mL) bearing terminal galactose in Tris buffered saline + 0.02% sodium azide are incubated with CMP-SA-PEG (0.75 mM) and 0.4 U/mL sialyltransferase (ST3Gal3 or ST3Gal4 for N-glycans on EPO and interferon beta; ST3Gal4, or ST3Gal1 for O-glycans on interferon alpha) at 32°C for 24 hours. Other transferases that may work include the 2,6 sialyltransferase from Photobacterium damsella. The acceptor peptide concentration is most preferably in the range of 0.1 mg/mL up to the solubility limit of the peptide. The concentration of CMP-SA-PEG should be sufficient for there to be excess over the available sites, but not so high as to cause peptide solubility problems due to the PEG, and may range from 50 µM up to 5 mM, and the temperature may range from 2°C up to 40°C. The time required for complete reaction will depend on the temperature, the relative amounts of enzyme to acceptor substrate, the donor substrate concentration, and the pH.

20

25

30

15

10

# 34. GlycoPEGylation of Interferon α produced in CHO cells

Preparation of Asialo-Interferon α. Interferon alpha produced from CHO cells is dissolved at 2.5 mg/mL in 50 mM Tris 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 5 mM CaCl<sub>2</sub> and concentrated to 500 μL in a Centricon Plus 20 centrifugal filter. The solution is incubated with 300 mU/mL Neuraminidase II (Vibrio cholerae) for 16 hours at 32 °C. To monitor the reaction a small aliquot of the reaction is diluted with the appropriate buffer and a IEF gel performed. The reaction mixture is then added to prewashed N-(p-aminophenyl)oxamic acid-agarose conjugate (800 μL/mL reaction volume) and the washed beads gently rotated for 24 hours at 4 °C. The mixture is centrifuged at 10,000 rpm and the supernatant was collected. The beads are washed 3 times with Tris-EDTA buffer, once with 0.4 mL Tris-EDTA buffer and all

supernatants were pooled. The supernatant is dialyzed at 4 °C against 50 mM Tris –HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub> and then twice more against 50 mM Tris –HCl pH 7.4, 1 M NaCl, 0.05% NaN<sub>3</sub>. The dialyzed solution is then concentrated using a Centricon Plus 20 centrifugal filter and stored at –20 °C. The conditions for the IEF gel are run according to the procedures and reagents provided by Invitrogen. Samples of native and desialylated G-CSF are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of Interferon-alpha-(alpha2,3)-Slalyl-PEG. Desialylated interferon-alpha is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaNs, pH 7.2. The solution is incubated with 1 mM CMP-sialic acid-PEG and 0.1 U/mL of ST3Gal1 at 32°C for 2 days. To monitor the incorporation of sialic acid-PEG, a small aliquot of the reaction had CMP-SA-PEG-fluorescent ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The fluorescent label incorporation into the peptide is quantitated using an in-line fluorescent detector. After 2 days, the reaction mixture is purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples of native and desialylated Interferon-alpha are dialyzed against water and analyzed by MALDI-TOF MS.

10

15

20

25

30

Preparation of Interferon-alpha-(alpha2,3)-Sialyl-PEG. Interferon-alpha produced in CHO, which contains an alpha2,3-sialylated O-linked glycan, is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 1 mM CMP-sialic acid-PEG and 0.1 U/mL of CST-II at 32°C for 2 days. To monitor the incorporation of sialic acid-PEG, a small aliquot of the reaction has CMP-SA-PEG-fluorescent ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The fluorescent label incorporation into the peptide is quantitated using an in-line fluorescent detector. After 2 days, the reaction mixture is purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis

according to the procedures and reagents supplied by Invitrogen. Samples of native and PEGylated interferon-alpha are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of Interferon-alpha-(alpha-2,6)-Sialyl-PEG. Interferon-alpha, containing only O-linked GalNAc, was dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 1 mM CMP-sialic acid-PEG and 0.1 U/mL of ST6GalNAcl or II at 32°C for 2 days. To monitor the incorporation of sialic acid-PEG, a small aliquot of the reaction had CMP-SA-PEG-fluorescent ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The fluorescent label incorporation into the peptide is quantitated using an in-line fluorescent detector. After 2 days, the reaction mixture is purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples of native and PEGylated interferon-alpha are dialyzed against water and analyzed by MALDI-TOF MS.

10

15

25

30

# 35. GlycoPEGylation of Interferon- $\beta$ -1a with PEG (10 kDa) and PEG (20 kDa)

This example illustrates a procedure PEGylate Interferon- $\beta$  with either PEG (10 kDa) or PEG (20 kDa).

Briefly, Interferon-β-1a (INF-β) was obtained from Biogen (Avonex<sup>TM</sup>). The IFN-β was first purified by Superdex-75 chromatography. The IFN-β was then desialylated with Vibrio cholerae sialidase. The INF-β was then PEGylated with SA-PEG (10 kDa) or SA-PEG (20 kDa) and purified with Superdex-200 chromatography.

Superdex-75 chromatography purification. INF-β (150 μg) was applied to a Superdex-75 column (Amersham Biosciences, Arlington Heights, IL) and eluted with PBS with 0.5 M NaCl, 0.02 Tween-20, 20 mM histidine and 10% glycerol. The eluant was monitored for absorbance at 280 nm (Figure 172A and 172B) and fractions were collected. Peaks 4 and 5 were pooled, concentrated in an Amicon Ultra 15 spin filter (Millipore, Billerica, MA), and the buffer was exchanged to TBS with 5 mM CaCl<sub>2</sub>, 0.02% Tween-20, 20 mM histidine and 10% glycerol.

Sialidase Reaction. The INF-β was then desialydated with Vibrio cholera salidase (70 mU/ml, CALBIOCHEM®, EMD Biosciences, Inc., San Diego, CA) on agarose in TBS with 5 mM CaCl<sub>2</sub>, 0.02% Tween-20, 20 mM histidine and 10% glycerol. The reaction was carried out at 32°C for 18 hours. The INF-β was removed from the agarose with a 0.22 μm Spin-X<sup>TM</sup> filter (Corning Technology, Inc., Norcross, GA). Figure 173A depicts the MALDI analysis of glycans released from native INF-β. The native INF-β has many glycoforms containing terminal sialic acid moieties. Figure 173B depicts the MALDI analysis of glycans released from desialylated INF-β. The desialylated INF-β has primarily one glycoform which is bi-antennary with terminal galactose moieties.

5

10

15

20

25

Lectin Dot-Blot Analysis of Sialylation. Samples of the INF-β from the desialidase reaction were dot-blotted onto nitrocellulose and then blocked with Tris buffered saline (TBS: 0.05M Tris, 0.15M NaCl, pH 7.5) and DIG kit (glycan differentiation kit available from Roche #1 210 238) blocking buffer. Some of the blots were incubated with Maackia amurensis agglutinin (MAA) labeled with digoxogenin (DIG) (Roche Applied Science, Indianapolis, IL) to detect α2,3-sialylation of INF-β. These blots were washed with TBS then incubated with anti-digitonin antibody labeled with alkaline phosphatase, then washed again with TBS and developed withNBT/X-phosphate solution, wherein NBT is 4-nitro blue tetrazolium chloride and X-phosphate is 5-bromo-4-chloro—3indoyl phosphate. The left side of Figure 174 depicts the results of the MAA blot of INF-β after the desialylation reaction. The INF-β is partially disialylated, as indicated by the decrease in dot development as compared to native INF-β in the desialylated samples.

Other blots were incubated with Erthrina cristagalli lectin (ECL) labeled with biotin (Vector Laboratories, Burlingame, CA) to detect exposed galactose residues on INF-\beta. After incubation with 2.5 \( \mu g/ml \) ECL, the blots were washed in TBS and incubated with streptavidin labeled with alkaline phosphatase. The blots were then washed again and developed. The right side of Figure 174 depicts the ECL blot after development. The increased intensity of the dot of desialylated INF-\beta as compared to the native INF-\beta indicate more exposed galactose moieties and therefore extensive desialylation.

PEGylation of Desialylated INF-β with SA-PEG (10 kDa). Desialylated INF-β
30 (0.05 mg/ml) was PEGylated with ST3Gal3 (50 mU/ml) and CMP-SA-PEG (10 kDa) (250

 $\mu$ M) in an appropriate buffer of TBS + 5 mM CaCl<sub>2</sub>, 0.02% Tween 20, 20 mM histidine, 10% glycerol for 50 hours at 32°C. Figure 175 depicts the SDS-PAGE analysis of the reaction products showing PEGylated INF- $\beta$  at approximately 98 kDa.

PEGylation of Desialylated INF-β with SA-PEG (20 kDa). Desialylated INF-β

5 (0.5 mg/ml) was PEGylated with ST3Gal3 (170 mU/ml) and CMP-SA-PEG (20 kDa) in an
appropriate buffer of TBS + 5 mM CaCl<sub>2</sub>, 0.02% Tween 20, 20 mM histidine, 10% glycerol
for 50 hours at 32°C. Figure 176 depicts the SDS-PAGE analysis the products of the
PEGylation reaction. The PEGylated INF-β has many higher molecular weight bands not
found in the unmodified INF-β indicating extensive PEGylation.

Superdex-200 Purification of INF-β PEGylated with PEG (10 kDa). The products of the PEGylation reaction were separated on a Superdex-200 column (Amersham Biosciences, Arlington Heights, IL) in PBS with 0.5 NaCl, 0.02 Tween-20, 20 mM histidine and 10% glycerol at 1ml/min and 30 cm/hr flow. The eluant was monitored for absorbance at 280 nm (Figure 177) and fractions were collected. Peaks 3 and 4 were pooled and concentrated in an Amicon Ultra 15 spin filter.

# Bioassay of INF-B PEGylated with PEG (10 kDa).

10

15

20

25

The test is inhibition of the proliferation of the lung carcinoma cell line, A549. The A549 cell line are lung carcinoma adherent cells growing in RPMI + 10% FBS at 37°C 5% CO<sub>2</sub>. They can be obtained from ATCC # CCL-185. Wash the cells with 10 ml of PBS and remove the PBS. Add 5 ml of trypsin, incubate for 5 minutes at room temperature or 2 minutes at 37°C. When the cells are detached resuspend into 25 ml of media and count the cells. Dilute the cells at a concentration of 10000 cells/ml and add 200 ul / well (96 wells plate). Incubate for 4 hours at 37°C 5% CO<sub>2</sub>. Prepare 1 ml of IFN B at a concentration of 0.1 ug/ml. Filter it under the hood with a 0.2 um filter. Add 100 ul per well (8 replicates = 1 lane). Incubate for 3 days (do not let the cells go to confluence). Remove 200 ul of media (only 100ul per well left). Add 25 µl of MTT (Sigma) (5 mg/ml filtered 0.22µm). Incubate for 4 hours at 37°C and 5% CO<sub>2</sub>. Aspirate the media gently and add 100 µl of a mixture of isopropanol (100 ml and 6N HCl. Aspirate up and down to homogenize the crystal violet. Read OD 570nm (remove the background at 630 or 690 nm).

Figure 178 depicts the results of the bioassay of the peaks containing INF- $\beta$  PEGylated with PEG (10 kDa) as eluted from the Superdex-200 column.

Superdex-200 Purification of INF-β PEGylated with PEG (20 kDa). The products of the PEG (20 kDa) PEGylation reaction were separated on a Superdex-200 column (Amersham Biosciences, Arlington Heights, IL) in PBS with 0.5 NaCl, 0.02 Tween-20, 20 mM histidine and 10% glycerol at 1 ml/min flow. The cluant was monitored for absorbance at 280 nm (Figure 179) and fractions were collected. Peak 3 contained most of the INF-β PEGylated with PEG (20 kDa).

# Endotoxin test of INF-B PEGylated with PEG (20 kDa).

Limulus Lysate Test was performed, BioWhittaker #50-647U

Table 24. Results of the endotoxin test of INF-β PEGylated with PEG (20 kDa).

	Concentration		
INF-β with PEG (20 kDa)	10 EU/ml	0.06 mg/ml	0.16 EU/μg
INF-β with PEG (20 kDa)	l EU/ml	0.07 mg/ml	0.014 EU/μg
Native INF-β	40 EU/ml	0.1 mg/ml	0.4 EU/μg

## Remicade<sup>TM</sup>

10

15

20

25

# 36. GlycoPEGylation of Remicade™ antibody

This example sets forth the procedure to glycoPEGylate a recombinant antibody molecule by introducing PEG molecules to the Fc region glycans. Here Remicade™, a TNF-R:IgG Fc region fusion protein, is the exemplary peptide.

Preparation of Remicade™—Gal-PEG (10 kDa). Remicade™ is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 5 mM MnCl<sub>2</sub>, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 1 mM UDP-galactose-PEG (10 kDa) and 0.1 U/mL of galactosyltransferase at 32°C for 2 days to introduce the PEG in the Fc region glycans. To monitor the incorporation of galactose, a small aliquot of the reaction has <sup>14</sup>C-galactose-UDP ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The radioactive label incorporation into the peptide is quantitated using an in-line radiation detector.

When the reaction is complete, the reaction mixture is purified using a Toso Haas TSK-Gel-3000 preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The fractions containing product are combined, concentrated, buffer exchanged and then freeze-dried. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

#### Rituxan<sup>TM</sup>

10

15

20

25

# 37. Glycoconjugation of geldanamycin to Rituxan™

This example sets forth the glycoconjugation of a small molecule, such as geldanamycin, to the Fc region glycans of an antibody produced in CHO cells, such as Rituxan $^{TM}$ . Here, the antibody Rituxan $^{TM}$  is used, but one of skill in the art will appreciate that the method can be used with many other antibodies.

Preparation of Rituxan™-Gal-linker-geldanamycin. Rituxan™ is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 5 mM MnCl<sub>2</sub>, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 1 mM UDP-galactose-linker-geldanamycin and 0.1 U/mL of galactosyltransferase at 32°C for 2 days to introduce the geldanamycin in the Fe region glycans. To monitor the incorporation of galactose, a small aliquot of the reaction has ¹⁴C-galactose-UDP ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The radioactive label incorporation into the peptide is quantitated using an in-line radiation detector.

When the reaction is complete, the reaction mixture is purified using a Toso Haas TSK-Gel-3000 preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The fractions containing product are combined, concentrated, buffer exchanged and then freeze-dried. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

Rnase

5

10

15

20

2.5

30

38. Remodeling high mannose N-glycans to hybrid and complex N-glycans: Bovine pancreatic RNase

This example sets forth the preparation of bovine pancreas RNase with hybrid or complex N-glycans. The high mannose N-linked glycans of the RNase are enzymatically digested and elaborated to create hybrid N-linked glycans. Additionally, the high mannose N-linked glycans of the RNase are enzymatically digested and elaborated to create complex N-linked glycans.

High mannose structures of N-linked oligosaccharides in glycopeptides can be modified to hybrid or complex forms using the combination of  $\alpha$ -mannosidases and glycosyltransferases. This example summarizes the results in such efforts using a simple N-Glycan as a model substrate.

Ribonuclease B (RNaseB) purified from bovine pancreas (Sigma) is a glycopeptide consisting of 124 amino acid residues. It has a single potential N-glycosylation site modified with high mannose structures. Due to its simplicity and low molecular weight (13.7 kDa to 15.5 kDa), ribonuclease B is a good candidate to demonstrate the feasibility of the N-Glycan remodeling from high mannose structures to hybrid or complex N-linked oligosaccharides. The MALDI-TOF spectrum of RNaseB (Figure 180A) and HPLC profile for the oligosaccharides cleaved from RNaseB by N-Glycanase (Figure 180B) indicated that, other than a small portion of the non-modified peptide, the majority of N-glycosylation sites of the peptide are modified with high mannose oligosaccharides consisting of 5 to 9 mannose residues.

Conversion of high mannose N-Glycans to hybrid N-Glycans. High mannose N-Glycans were converted to hybrid N-Glycans using the combination of  $\alpha 1,2$ -mannosidase, GleNAcT-I ( $\beta -1,2$ -N-acetyl glucosaminyl transferase), GalT-I ( $\beta 1,4$ -galactosyltransfease) and  $\alpha 2,3$ -sialyltransferase /or  $\alpha 2,6$ -sialyltransferase as shown in Figure 181.

As an example, high mannose structures in RNaseB were successfully converted to hybrid structures.

Man<sub>5</sub>GlcNAc<sub>2</sub>-R was obtained from Man<sub>5</sub>glcNAc<sub>2</sub>-R catalyzed by a single α1,2mannosidase cloned from *Trichoderma reesei* (Figure 182). RNase B (1 g, about 67 μmol) was incubated at 30°C for 45 hr with 15 mU of the recombinant *T. reesei* α1,2-mannosidase

in MES buffer (50 mM, pH 6.5) in a total volume of 10 mL.  $Man_{69}GlcNAc_2$ -protein structures have been successfully converted to  $Man_{5}GlcNAc_2$ -protein with high efficiency by the recombinant mannosidase.

Alternately, Man<sub>5</sub>GlcNAc<sub>2</sub>-R was obtained from Man<sub>5</sub>-glcNAc<sub>2</sub>-R catalyzed by a single α1,2-mannosidase purified from Aspergillus saitoi (Figure 183). RNase B (40 μg, about 2.7 nmol) was incubated at 37°C for 42.5 hr with 25 μU of the commercial A. saitoi α1,2-mannosidase (Glyko or CalBioChem) in NaOAC buffer (100 mM, pH 5.0) in a total volume of 20 μl. Man<sub>6</sub>-glcNAc<sub>2</sub>-protein structures were successfully converted to Man<sub>5</sub>GlcNAc<sub>2</sub>-protein by the commercially available mannosidase. However, a new peak corresponding to the GlcNAc-protein appears in the spectrum, indicating the possible contamination of endoglycosidase H in the preparation. Although several mammalian alphamannosidases were required to achieve this step, the fungal α1,2-mannosidase was very efficient to remove all α1,2-linked mannose residues.

5

10

15

20

25

30

GlcNAcT-I then added a GlcNAc residue to the Man<sub>5</sub>GlcNAc<sub>2</sub>-R (Figure 184). The reaction mixture after the  $\it T.$  reeset a1,2-mannosidase reaction containing RNase B (600  $\mu g$ , about 40 nmol) was incubated with non-purified recombinant GlcNAcT-I (34 mU) in MES buffer (50 mM, pH 6.5) containing MnCl<sub>2</sub> (20 mM) and UDP-GlcNAc (5 mM) in a total volume of 400  $\mu l$ . at 37°C for 42 hr. A GlcNAc residue was quantitatively added to Man<sub>5</sub>GlcNAc<sub>2</sub>-protein by the recombinant GlcNAcT-I.

A Gal residue was then added using GalT 1 (Figure 185). The reaction mixture after the GnT-I reaction containing RNase B (120  $\mu$ g, about 8 nmol) was incubated at 37°C for 20 hr with 3.3 mU of the recombinant GalT-1 in Tris-HCl buffer (100 mM, pH 7.3) containing UDP-Gal (7.5 mM) and MnCl<sub>2</sub> (20 mM) in a total volume of 100  $\mu$ l. A Gal residue was added to about 98% of the GlcNAc-Man<sub>3</sub>GlcNAc<sub>2</sub>-protein by the recombinant GalT 1.

The next step was the addition of a sialic acid using an  $\alpha 2,3$ -sialyltransferase or an  $\alpha 2,6$ -sialyltransferase (Figure 186). As an example, ST3Gal III, an  $\alpha 2,3$ -sialyltransferase was used. The reaction mixture after the GaIT-1 reaction containing RNase B (13  $\mu g$ , about 0.87 nmol) was incubated at 37°C for 16 hr with 8.9 mU of recombinant ST3Gal III in Tris-HCl buffer (100 mM, pH 7.3) containing CMP-Sialic acid (5 mM) and MnCl<sub>2</sub> (20 mM) in a total volume of 20  $\mu$ l. A sialic acid residue was added to about 90% of the Gal-GlcNAc-

Man<sub>5</sub>GlcNAc<sub>2</sub>-protein by recombinant ST3Gal III using CMP-SA as the donor. The yield can be further improved by adjusting the reaction conditions.

For convenience, no purification or dialysis step was required after each reaction described above. More interesting, GaIT 1 and ST3GaI III can be combined in a one-pot reaction. Similar yields were obtained as compared with the separate reactions. The reaction mixture after the GlcNAcT-1 reaction containing RNase B (60 µg, about 4 nmol) was incubated at 37°C for 20 hr with 1.7 mU of recombinant GaIT 1, 9.8 mU of recombinant ST3GaI III in Tris-HCl buffer (100 mM, pH 7.3) containing UDP-GaI (7.5 mM), CMP-sialic acid (5 mM) and MnCl<sub>2</sub> (20 mM) in a total volume of 60 µl.

As shown in Figure 187, SA-PEG (10 kDa) was successfully added to the RNaseB. The reaction mixture after the GalT-1 reaction containing RNase B (6.7 μg, about 0.45 nmol) was dialyzed against H<sub>2</sub>O for 1 hour at room temperature and incubated at 37°C for 15.5 hours with 55 mU of the recombinant ST3Gal III in Tris-HCl buffer (50 mM, pH 7.3) containing CMP-SA-PEG (10 kDa) (0.25 mM) and MnCl<sub>2</sub> (20 mM) in a total volume of 20 μl. PEG-modified sialic acid residues were successfully added to the Gal-GlcNAc-Man<sub>5</sub>GlcNAc<sub>2</sub>-peptide by the recombinant ST3Gal III. The yield can be further improved by adjusting the reaction conditions.

10

15

25

30

Conversion of high mannose N-Glycans to complex N-Glycans. To achieve this conversion, a GlcNAcβ1,2Man<sub>3</sub>GlcNAc<sub>2</sub>-peptide intermediate is obtained. As shown in

20 Figure 188, there are at least four feasible routes to carry out the reaction from Man<sub>3</sub>GlcNAc<sub>2</sub>-peptide to this intermediate:

Route I: The Man<sub>5</sub>GlcNAc<sub>2</sub>-peptide produced by the fungal  $\alpha$ 1,2 mannosidase is a substrate of GlcNAc transferase I (GlcNAcT-I, enzyme 2) which adds one GlcNAc. The terminal  $\alpha$ 1,3- and  $\alpha$ 1,6-linked mannose residues of GlcNAcMan<sub>5</sub>GlcNAc<sub>2</sub>-peptide is removed by Golgi  $\alpha$ -mannosidase II (ManII, enzyme 5). This route is a part of the natural pathway for the processing of N-linked oligosaccharides carried out in higher organisms.

Route II: Two mannose residues are first removed by an α-mannosidase (enzyme 6), then a GlcNAc is added by GlcNAcT-I (enzyme 2). Other than its natural acceptor Man<sub>5</sub>GlcNAc<sub>2</sub>-R, GlcNAcT-I can also recognize Man<sub>3</sub>GlcNAc<sub>2</sub>-R as its substrate and add one GlcNAc to the mannose core structure to form GlcNAcMan<sub>3</sub>GlcNAc<sub>2</sub>-peptide.

Route III: The  $\alpha$ 1,6-linked mannose is removed by an  $\alpha$ 1,6-mannosidase, followed by the addition of GleNAc by GleNAcT-I and removal of the terminal  $\alpha$ 1,3-linked mannose by an  $\alpha$ 1,3-mannosidase. From the experimental data obtained, GleNAcT-I can recognize this Man<sub>4</sub>GleNAc<sub>2</sub>-peptide as acceptor and add one GleNAc residue to form GleNAcMan<sub>4</sub>GleNAc>-peptide.

Route IV: Similar to Route III,  $\alpha$ 1,3-linked mannose is removed by an  $\alpha$ 1,3-mannosidase, followed by GlcNAcT-I reaction. Then the terminal  $\alpha$ 1,6-linked mannose can be removed by an  $\alpha$ 1,6-mannosidase.

After the function of GlcNAcT-I (responsible for the addition of the GlcNAc  $\beta$ 1,2-linked to the  $\alpha$ 1,3-mannose on the mannose core) and GlcNAcT-II (responsible for the addition of a second GlcNAc  $\beta$ 1,2-linked to the  $\alpha$ 1,6-mannose on the mannose core), the GlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub>-peptide can be processed by GaIT 1 and sialyltransferase to form biantennary complex N- Glycans. Other GlcNAc transferases such as GlcNAcT-IV, GlcNAcT-V, and/or GlcNAcT-VI (Figure 188 and Figure 189) can also glycosylate the GlcNAc<sub>2</sub>Man<sub>3</sub>GlcNAc<sub>2</sub>-peptide. Additional glycosylation by the GaIT 1 and sialyltransferases will form multi-antennary complex N-glycans. The enzyme GlcNAcT-III catalyzes the insertion of a bisecting GlcNAc, thus preventing the actions of ManII and subsequent action of transferases GlcNAcT-II, GlcNAcT-IV and GlcNAcT-V.

## Tissue-Type Plasminogen Activator (TPA)

5

10

15

20

25

30

39. Fucosylation of TPA to create Sialyl Lewis X

This example sets forth the preparation of Tissue Tissue-type Plasminogen Activator (TPA) with N-linked sialyl Lewis X antigen.

Sialylation. TPA expressed in mammalian cells will often contain a majority of the glycans terminating in sialic acid, but to ensure complete sialylation, it would be beneficial to first perform an in vitro sialylation. TPA in a suitable buffer (most preferably between pH 5.5 and 9, for example Tris buffered saline, pH 7.2) is incubated with CMP sialic acid and sialyltransferase for a time sufficient to convert any glycans lacking sialic acid to sialylated species. Typical conditions would be 1 mg/mL TPA, 3 mM CMP sialic acid, 0.02 U/mL ST3Gal3, 32°C for 24 hours. Microbial growth can be halted either by sterile filtration or the

inclusion of 0.02% sodium azide. The TPA concentration is most preferably in the range 0.1 mg/mL up to the solubility limit of the peptide. The concentration of CMP-SA should be sufficient for there to be excess over the available sites, and might range from 50  $\mu M$  up to 50 mM, and the temperature from 2°C up to 40°C. The time required for complete reaction will depend on the temperature, the relative amounts of enzyme to acceptor substrate, the donor substrate concentration, and the pH. Other sialyltransferases that may be capable of adding sialic acid in 2,3 linkage include ST3Gal4; microbial transferases could also be used.

Fucosylation. Typical conditions for fucosylation would be 1 mg/mL TPA, 3 mM GDP-fucose, 0.02 U/mL FTVI, 5 mM MnCl<sub>2</sub>, 32°C for 24H in Tris buffered saline. Microbial growth can be halted either by sterile filtration or the inclusion of 0.02% sodium azide. The TPA concentration is most preferably in the range 0.1 mg/mL up to the solubility limit of the peptide. The concentration of GDP-fucose should be sufficient for there to be excess over the available sites, and might range from 50 µM up to 50 mM, and the temperature from 2°C up to 40°C. The time required for complete reaction will depend on the temperature, the relative amounts of enzyme to acceptor substrate, the donor substrate concentration, and the pH. Other fucosyltransferases that may be capable of making sialyl Lewis x include FTVII, FTV, FTIII, as well as microbial transferases could also be used.

10

15

20

25

# 40. Trimming of high mannose to tri-mannose core structure: Tissue-type Plasminogen Activator produced in CHO

This example sets forth the preparation of Tissue-type Plasminogen Activator with a trimannose core by trimming back from a high mannose glycan.

Tissue-type plasminogen activator (TPA) is currently produced in Chinese Hamster Ovary (CHO) cells and contains a low amount of high mannose N-linked oligosaccharide. The mannoses can be trimmed down using a variety of the specific mannosidases. The first step is to generate Man5GlcNAc2(Fuc0-1) from Man9GlcNAc2(Fuc0-1). This can be done using mannosidase I. Then either GlcNAcT1 (GlcNAc transferase I) is used to make GlcNAc1Man5GlcNAc2(Fuc0-1) or Mannosidase III is used to make Man3GlcNAc2(Fuc0-1). From Man3GlcNAc2(Fuc0-1), GlcNAc1Man3GlcNAc2(Fuc0-1) can be produced using GlcNAcT1 or from GlcNAc1Man5GlcNAc2(Fuc0-1), GlcNAc1Man3GlcNAc2(Fuc0-1) can 30 be produced using Mannosidase II. GlcNAc1Man3GlcNAc2(Fuc0-1) is then converted into

GlcNAc2Man3GlcNAc2(Fuc0-1) using GlcNAcTransferase II (GlcNAcTII). The two terminal GlcNAc residues are then galactosylated using GalTI and then sialylated with SA-PEG using ST3GalIII.

Conversely, TPA can be produce in yeast or fungal systems. Similar processing would be required for fungal derived material.

# 41. Generation and PEGylation of GlcNAc-ASN structures; TPA produced in Vegst

This example sets forth the preparation of PEGylated GlcNAc-Asn structures on a 10 peptide such as TPA expressed in yeast.

Yeast expression is expected to result in a TPA which contains a single N-linked mannan-type structure. This recombinant glycoprotein is first treated with endoglycosidase H to generate GlcNAc structures on the asparagine (Asn) residues on the peptide.

The GlcNAc-Asn structures on the peptide/protein backbone are then be modified with galactose or galactose-PEG using UDP-galactose or UDP-galactose-6-PEG, respectively, and a galactosyltransferase such as GalT1. In one case, the galactose-PEG is the terminal residue. In the second case, the galactose is further modified with SA-PEG using a CMP-SA-PEG donor and a sialyltransferase such as ST3GalIII. In another embodiment, the GlcNAc-Asn structures on the peptide/protein backbone may be galactosylated and sialylated as described above, and then further sialylated using CMP-SA-PEG and an α2,8-sialyltransferase such as the enzyme encoded by the Campylobacter jejunicst-II gene.

#### Transferrin

15

20

25

30

## 42. GlycoPEGylation of Transferrin

This example sets forth the preparation of asialotransferrin and its sialylation with PEG-CMP-sialic acid.

Preparation of Asialo-transferrin. Human-derived holo-Transferrin, (10 mg) was dissolved in 500 µL of 50 mM NaOAc, 5 mM CaCl<sub>2</sub>, pH 5.5. To this solution was added 500 mU Neuraminidase II (Vibrio cholerae) and the reaction mixture was shaken gently for 20.5 hours at 37 °C. The reaction mixture was added to the prewashed N-(p-

aminophenyl)oxamic acid-agarose conjugate (600  $\,\mu$ L) and the washed beads gently rotated for 24 hours at 4 °C. The mixture was centrifuged at 10,000 rpm and the supernatant was collected. The reaction mixture was adjusted to 5 mM EDTA by addition of 100  $\,\mu$ L of 30 mM EDTA to the washed beads, which were gently rotated for 20 hours at 4 °C. The suspension was centrifuged for 2 minutes at 10,000 rpm and the supernatant was collected. The beads were washed 5 times with 0.35 mL of 50 mM NaOAc, 5 mM CaCl<sub>2</sub>, 5 mM EDTA, pH 5.5 and all supernatants were pooled. The enzyme solution was dialyzed twice at 4 °C into 15 mM Tris-HCl, 1 M NaCl, pH 7.4. 0.3 mL of the transferrin solution (3.3 mL total) was removed and dialyzed twice against water. The remainder was dialyzed twice more at 4 °C against phosphate buffered saline. The dialyzed solution was stored at -20 ° C. Protein samples were analyzed by IEF Electrophoresis. Samples (9  $\,\mu$ L, 25  $\,\mu$ g) were diluted with 16  $\,\mu$ L Tris buffer and mixed with 25  $\,\mu$ L of the sample loading buffer and applied to Isoelectric Focusing Gels (pH 3-7). Gels were run and fixed using standard procedures. Gels were stained with Colloidal Blue Stain.

Sialyl-PEGylation of asialo-Transferrin. Desialylated transferrin (250 μg) and CMP-sialic acid or CMP-SA-PEG (1 kDa or 10 kDa)(0.05 μmol) were dissolved in 69 μL 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN3, pH 7.2 in 1.5 mL plastic tubes. The tubes were vortexed briefly and 100 mU ST3Gal3 (90 μ L) were added (total volume 250 μ L). The tubes were vortexed again and mixed gently for 24 hours at 32 °C. The reactions were stopped by freezing at -80 °C. Novex Tris-Glycine 8-16% 1 mm gels were used for SDS PAGE analysis (Figure 190). Samples (25 μL, 25 μg) were mixed with 25 μL of sample loading buffer and 0.4 μL of β-mercaptoethanol and heated for 6 minutes at 85 °C. Gels were run using standard conditions and stained with Colloidal Blue Stain. IEF gels were also performed as described above Figure 191). Samples were also dialyzed against water analyzed by MALDI-TOF.

Results. MALD1 was also performed. Native transferrin (78729); asialotransferrin (78197); resialylated transferrin (79626/80703); with SA-PEG 1k (79037 (1); 80961 (2); 82535 (3); 84778 (4)); with SA-PEG 5k (90003 (2); 96117 (3); 96117 (4)); with SA-PEG 10k (100336 (2); 111421 (3); 122510 (4)).

25

5

10

15

20

#### 43. Transferrin-GDNF

10

15

20

25

30

This example sets forth the procedures for the glycoconjugation of proteins, and in particular, transferrin is glycoconjugated to GDNF. Transferrin-SA-Linker-Gal-UDP is prepared from transferrin. The galactose residue is removed from GNDF glycans, and Transferrin-SA-Linker-Gal-UDP is conjugated to GNDF glycans using a galactosyltransferase.

Preparation of agalacto-GDNF. GDNF produced in NSO cells (NSO murine myeloma cells) is dissolved at 2.5 mg/mL in 50 mM Tris 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, and is incubated with 300 mU/mL beta-galactosidase-agarose conjugate for 16 hours at 32°C. To monitor the reaction a small aliquot of the reaction is diluted with the appropriate buffer and a IEF gel performed according to Invitrogen procedures. The mixture is centrifuged at 10,000 rpm and the supernatant is collected. The supernatant is dialyzed at 4 °C against 50 mM Tris-HCl pH 7.4, 1 M NaCl, 0.05% NaN3 and then twice more against 50 mM Tris-HCl pH 7.4, 1 M NaCl, 0.05% NaN3. The dialyzed solution is then concentrated using a Centricon Plus 20 centrifugal filter and stored at -20 °C. The conditions for the IEF gel are run according to the procedures and reagents provided by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of Transferrin-SA-Linker-Gal-UDP. Asialo-transferrin is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with CMP-sialic acid-linker-Gal-UDP (molar amount to add 1 molar equivalent of nucleotide sugar to transferrin) and 0.1 U/mL of ST3Gal3 at 32°C for 2 days. To monitor the incorporation of sialic acid, a small aliquot of the reaction has <sup>14</sup>C-SA-UDP ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Hass G3000SW analytical column using PBS buffer (pH 7.1). The radioactive label incorporation into the peptide is quantitated using an in-line radiation detector.

The solution is incubated with 5 mM CMP-sialic acid and 0.1 U/mL of ST3Gal3 (to cap any unreacted transferrin glycans) at 32°C for 2 days. The incorporation into the peptide is quantitated using an in-line UV detector. After 2 days, the reaction mixture is purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) and collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE

and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

Preparation of Transferrin-SA-Linker-Gal-GDNF. The transferrin-SA-Linker-Gal-UDP prepared as described above is dissolved at 2.5 mg/mL in 50 mM Tris-HCl, 0.15 M NaCl, 5 mM MnCl<sub>2</sub>, 0.05% NaN<sub>3</sub>, pH 7.2. The solution is incubated with 2.5 mg/mL agalacto-GDNF and 0.1 U/mL of galactosyltransferase at 32°C for 2 days. To monitor the incorporation of galactose, a small aliquot of the reaction has <sup>14</sup>C-galactose-UDP ligand added; the label incorporated into the peptide is separated from the free label by gel filtration on a Toso Haas G3000SW analytical column using PBS buffer (pH 7.1). The radioactive label incorporation into the peptide is quantitated using an in-line radiation detector.

10

15

20

25

When the reaction is complete, the solution is incubated with 5 mM UDP-Gal and 0.1 U/mL of galactosyltransferase (to cap any unreacted transferrin glycans) at 32°C for 2 days followed by addition of 5 mM CMP-SA and 0.1 U/mL of ST3Gal3. After 2 additional days, the reaction mixture is purified using a Toso Haas G3000SW preparative column using PBS buffer (pH 7.1) collecting fractions based on UV absorption. The product of the reaction is analyzed using SDS-PAGE and IEF analysis according to the procedures and reagents supplied by Invitrogen. Samples are dialyzed against water and analyzed by MALDI-TOF MS.

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

#### What is claimed:

2.0

 An EPO peptide comprising one or more glycans, having a glycoconjugate molecule covalently attached to said peptide.

- The EPO peptide of claim 1, wherein said one or more glycans is a
   monoantennary glycan.
  - 3. The EPO peptide of claim 1, wherein said one or more glycans is a biantennary glycan.
  - 4. The EPO peptide of claim 1, wherein said one or more glycans is a triantennary glycan.
- 5. The EPO peptide of claim 1, wherein said one or more glycans is at least a triantennary glycan.
  - The EPO peptide of claim 1, wherein said one or more glycans comprises at least two glycans comprising a mixture of mono or multiantennary glycans.
- The EPO peptide of claim 1, wherein said one or more glycans is selected
   from an N-linked glycan and an O-linked glycan.
  - The EPO peptide of claim 1, wherein said one or more glycans is at least two glycans selected from an N-linked and an O-linked glycan.
  - The EPO peptide of claim 1, wherein said peptide is expressed in a cell selected from the group consisting of a prokaryotic cell and a eukaryotic cell.
  - 10. The EPO peptide of claim 9, wherein said eukaryotic cell is selected from the group consisting of a mammalian cell, an insect cell and a fungal cell.
    - 11. The EPO peptide of claim 10, wherein said fungal cell is a yeast cell.
    - A glycoPEGylated EPO peptide comprising an EPO peptide and at least one glycan and at least one poly(ethylene glycol) molecule covalently attached to said glycan,

wherein said poly(ethylene glycol) molecule is added to said EPO peptide using a glycosyltransferase.

The glycoPEGylated EPO peptide of claim 12, comprising at least one
 mono-antennary glycan.

- 14. The glycoPEGylated EPO peptide of claim 12, wherein all of said glycans are N-linked and are mono-antennary.
- 10 15. The glycoPEGylated EPO peptide of claim 12, wherein all of said glycans are N-linked and at least one of said glycans comprise said poly(ethylene glycol).
  - 16. The glycoPEGylated EPO peptide of claim 15, wherein more than one of said glycans comprises said poly(ethylene glycol).
- 15
  17. The glycoPEGylated EPO peptide of claim 12, wherein all of said glycans are N-linked and all of said glycans comprise said poly(ethylene glycol).
- 18. The glycoPEGylated EPO peptide of claim 12, comprising at least three 20 mono-antennary glycans having said poly(ethylene glycol) covalently attached thereto.
  - A glycoPEGylated EPO peptide, wherein said EPO peptide comprises three or more glycans.
- 25 20. The glycoPEGylated EPO peptide of claim 9, wherein at least one of said glycans comprises said poly(ethylene glycol) covalently attached thereto.
  - The glycoPEGylated EPO peptide of claim 18, wherein more than one of said glycans comprises said poly(ethylene glycol) covalently attached thereto.

 The glycoPEGylated EPO peptide of claim 18, wherein all of said glycans comprise said poly(ethylene glycol) covalently attached thereto.

- 23. The glycoPEGylated EPO peptide of claim 12 wherein said poly(ethylene glycol) is linked to at least one sugar moiety selected from the group consisting of fucose (Fue), N-acetylglucosamine (GlcNAc), galactose (Gal) and a sialic acid (SA).
  - The glycoPEGylated EPO peptide of claim 23, wherein said sialic acid is N-acetylneuraminic acid.
- 10 25. The glycoPEGylated EPO peptide of claim 12, wherein said EPO peptide does not comprise an O-linked glycan.
  - The glycoPEGylated EPO peptide of claim 12 wherein said EPO peptide comprises at least one O-linked glycan.
- 15 27. The glycoPEGylated EPO peptide of claim 26, wherein said O-linked peptide comprises said poly(ethylene glycol) covalently attached thereto.
- 28. The glycoPEGylated EPO peptide of claim 27, wherein said EPO peptide 20 is recombinantly expressed in a cell.
  - 29. The glycoPEGylated EPO peptide of claim 28, wherein said cell is selected from the group consisting of an insect cell, a fungal cell and a mammalian cell.
- 25 30. The glycoPEGylated EPO peptide of claim 29, wherein said fungal cell is a yeast cell.
  - The glycoPEGylated EPO peptide of claim 29, wherein said cell is an insect cell.

32. The glycoPEGylated EPO peptide of claim 29, wherein said cell is a yeast cell.

- 33. The glycoPEGylated EPO peptide of claim 29, wherein said cell is a mammalian cell.
  - 34. The glycoPEGylated EPO peptide of claim 33, wherein said mammalian cell is a CHO cell.
  - 35. The glycoPEGylated EPO peptide of claim 12, wherein said poly(ethylene glycol) has a molecular weight selected from the group consisting of about 1 kDa, 2 kDa, 5 kDa, 10 kDa, 20 kDa, 30 kDa and 40 kDa.
- 36. The glycoPEGylated EPO peptide of claim 35, wherein said poly(ethylene
   glycol) has a molecular weight of 20 kDa.
  - 37. The glycoPEGylated EPO peptide of claim 12, wherein said EPO peptide is selected from the group consisting of a naturally occurring EPO peptide and a mutated EPO peptide.
  - 38. The glycoPEGylated EPO peptide of claim 37, wherein said mutated EPO peptide comprises the amino acid sequence of SEQ ID NO:73 having at least one mutation selected from the group consisting of Arg<sup>139</sup> to Ala<sup>139</sup>, Arg<sup>143</sup> to Ala<sup>143</sup> and Lys<sup>154</sup> to Ala<sup>154</sup>.
- 25 39. A method of making a glycoPEGylated EPO peptide, said method comprising the step of:
  - (a) contacting an EPO peptide with a mixture comprising a nucleotide sugar covalently linked to poly(ethylene glycol) and a glycosyltransferase under conditions sufficient to transfer said poly(ethylene glycol) to said EPO peptide.

20

10

40. The method of claim 39, wherein the sugar of said nucleotide sugar is selected from the group consisting of fucose (Fuc), N-acetylglucosamine (GlcNAc), galactose (Gal) and a sialic acid (SA).

- 5 41. The method of claim 40, wherein said sialic acid is N-acetylneuraminic acid (NAN).
- 42. The method of claim 39, wherein said poly(ethylene glycol) has a
  molecular weight selected from the group consisting of about 1 kDa, 2 kDa, 5 kDa, 10 kDa,
  10 20 kDa, 30 kDa and 40 kDa.
  - 43. The method of claim 42, wherein said poly(ethylene glycol) has a molecular weight of 20 kDa.
- 15 44. The method of claim 39, wherein said EPO peptide is recombinantly expressed in a cell.
  - 45. The method of claim 44, wherein said cell is selected from the group consisting of an insect cell, a fungal cell and a mammalian cell.

20

25

- 46. The method of claim 45, wherein said cell is an insect cell.
  - 47. The method of claim 45, wherein said cell is a yeast cell.
- 48. The method of claim 45, wherein said cell is a mammalian cell.
  - 49. The method of claim 48, wherein said mammalian cell is a CHO cell.
- 50. The method of claim 39, wherein said EPO peptide is selected from the group consisting of a naturally occurring EPO peptide and a mutated EPO peptide.

 The method of claim 50, wherein said mature EPO peptide has the sequence of SEQ ID NO:73.

- 52. The method of claim 50, wherein said mutated EPO peptide comprises the amino acid sequence of SEQ ID NO: 73 having at least one mutation selected from the group consisting of Arg<sup>139</sup> to Ala<sup>139</sup>, Arg<sup>143</sup> to Ala<sup>143</sup> and Lys<sup>154</sup> to Ala<sup>154</sup>.
  - 53. The method of claim 39, wherein before step (a):
- (b) contacting said EPO peptide with a mixture comprising a nucleotide-Nacetylglucosamine (GlcNAc) molecule and an N-acetylglucosamine transferase (GnT) for which the nucleotide-GlcNAc is a substrate under conditions sufficient to form a bond between said GlcNAc and said EPO, wherein said GnT is selected from the group consisting of GnT I, GnT II, GnT III, GnT IV, GnT V and GnT VI.
- 15 54. The method of claim 53, wherein said mixture comprises one GnT selected from the group consisting of GnT I, GnT II, GnT IV, GnT V and GnT VI.
  - 55. The method of claim 54, wherein said GnT is GnT I.
- 20 56. The method of claim 54, wherein said GnT is GnT II.

30

- The method of claim 39, wherein said glycoPEGylated EPO peptide comprises at least one mono-antennary glycan.
- 25 58. The method of claim 39, wherein the sugar of said nucleotide sugar is galactose and said glycosyltransferase is galactosyl transferase I (GaIT I).
  - 59. The method of claim 53, wherein before step (a) but after step (b): (c) contacting said EPO peptide with a mixture comprising a nucleotide galactose (Gal) and galactosyl transferase I (GalT I) under conditions sufficient to transfer galactose to said EPO peptide.

60. The method of claim 39, wherein in step (a), the sugar of said nucleotide sugar is sialic acid and said glycosyltransferase is a sialyltransferase.

- 5 61. The method of claim 60, wherein said sialic acid is N-acetylneuraminic acid (NAN).
- 62. The method of claim 60, wherein said sialyltransferase is selected from the group consisting of  $\alpha(2,3)$ sialyltransferase,  $\alpha(2,6)$ sialyltransferase and 10 (2,8)sialyltransferase.
  - 63. A glycoPEGylated EPO peptide made by the method of claim 39.
- A glycoPEGylated EPO peptide, said EPO peptide comprising the
   sequence of SEQ ID NO:73.
  - 65. A glycoPEGylated EPO peptide, said EPO peptide comprising the sequence of SEQ ID NO:73 and further comprising a mutation in said sequence.
  - 66. A method of making a glycoPEGylated EPO peptide, said method comprising the steps of:

20

25

30

- (a) contacting an EPO peptide with a mixture comprising a nucleotide sugar covalently linked to poly(ethylene glycol) and a glycosyltransferase under conditions sufficient to transfer said poly(ethylene glycol) to said EPO peptide, wherein said glycosyltransferase is a fucosyltransferase.
- 67. The method of claim 66, wherein said fucosyltransferase is selected from the group consisting of fucosyltransferase I, fucosyltransferase III, fucosyltransferase IV, fucosyltransferase V, fucosyltransferase VII.

68. A glycoPEGylated EPO peptide made by the method of claim 66.

69. The method of claim 66, wherein said EPO peptide is expressed in a CHO cell.

- 5 70. A method of treating a mammal having anemia, said method comprising administering to said mammal an EPO peptide having one or more glycans having a glycoconjugate molecule attached to said peptide, wherein said EPO peptide is administered in an amount effective to increase the hematocrit level in said mammal.
  - 71. The method of claim 70, wherein said mammal is a human.
  - 72. A method of providing crythropoietin therapy to a mammal, said method comprising administering an effective amount of a glycoPEGylated EPO peptide comprising an EPO peptide and at least one glycan and at least one poly(ethylene glycol) molecule covalently attached to said glycan, wherein said poly(ethylene glycol) molecule is added to said EPO peptide using a glycosyltransferase, wherein said EPO peptide is administered in an amount effective to increase the hematocrit level in said mammal.
    - 73. The method of claim 72, wherein said mammal is a human.
- 74. A method of treating a mammal having anemia, said method comprising administering to said mammal a glycoPEGylated EPO peptide comprising an EPO peptide and at least one glycan and at least one poly(ethylene glycol) molecule covalently attached to said glycan, wherein said poly(ethylene glycol) molecule is added to said EPO peptide using a glycosyltransferase, wherein said EPO peptide is administered in an amount effective to increase the hematocrit level in said mammal.
  - 75. The method of claim 74, wherein said mammal is a human.


10

15


20

 $76. \ \ \mbox{The method of claim } 75, \mbox{wherein said anemia is associated with chemotherapy}.$ 

77. A method of treating a kidney dialysis patient, said method comprising administering to said patient a glycoPEGylated EPO peptide comprising an EPO peptide and at least one glycan and at least one poly(ethylene glycol) molecule covalently attached to said glycan, wherein said poly(ethylene glycol) molecule is added to said EPO peptide using a glycosyltransferase, wherein said EPO peptide is administered in an amount effective to increase the hematocrit level in said patient.



2/498







FIG. 3










FIG. 6









9/498












FIG. 13








FIG. 15




FIG. 16








FIG: 17















FIG. 20











FIG. 23C







FIG. 25





Sialic acid Nacetylglucosamine Galactose Omannose

FIG. 27

12AP1/E5 -- Viventia Biotech 1964 -- Aventis 20K growth hormone -- AMUR 28P6/E6 -- Viventia Biotech 3-Hydroxyphthaloyl-beta-lactoglobulin -4-IBB ligand gene therapy -64-Cu MAb conjugate TETA-1A3 --Mallinckrodt Institute of Radiology 64-Cu MAb conjugate TETA-cT84.66 64-Cu Trastuzumab TETA conjugate – Genentech A 200 -- Amgen A10255 - Eli Liliy A1PDX - Hedral Therapeutics A6 -- Anastrom aaAT-III -- Genzyme Abciximab -- Centocor ABI,001 - Atlantic BioPharmaceuticals ART-828 - Abbott Accutin Actinohivin activin -- Biotech Australia, Human Therapeutics, Curis AD 439 - Tanox AD 519 - Tanox Adalimumab -- Cambridge Antibody Tech. Adenocarcinoma vaccine - Biomira - NIS Adenosine deanimase -- Enzond Adenosine A2B receptor antagonists --Adenosine Therapeutics ADP-001 - Axis Genetics AF 13948 - Affymax Afelimomab – Knoll AFP-SCAN - Immunomedics AG 2195 - Corixa agalsidase alfa - Transkaryotic Therapies agalsidase beta -- Genzyme AGENT- Antisoma Al 300 - Autolmmune Al-101 - Teva Al-102 - Teva

AI-201 - AutoImmune AI-301 - AutoImmune AIDS vaccine - ANRS, CIBG, Hesed Biomed, Hollis-Eden, Rome, United Biomedical, American Home Products, Maxvgen airway receptor ligand -- IC Innovations AJvW 2 -- Ajinomoto AK 30 NGF -- Alkermes Albuferon -- Human Genome Sciences albumin - Biogen, DSM Anti-Infectives, Genzyme Transgenics, PPL Therapeutics, TranXenoGen, Welfide Corp. aldesleukin -- Chiron alefacept -- Biogen Alemtuzumab Allergy therapy -- ALK-Abello/Maxygen, ALK-Abello/RP Scherer allergy vaccines -- Allergy Therapeutics Alnidofibatide -- Aventis Pasteur Alnorine - SRC VB VECTOR ALP 242 - Gruenenthal Alpha antitrypsin -- Arriva/Hyland Immuno/ProMetic/Protease Sciences Alpha-1 antitrypsin - Cutter, Bayer, PPL Therapeutics, Profile, ZymoGenetics, Arriva Alpha-1 protease inhibitor -- Genzyme Transgenics, Welfide Corp. Alpha-galactose fusion protein -Immunomedics Alpha-galactosidase A -- Research Corporation Technologies, Genzyme Alpha-glucosidase - Genzyme, Novazyme Alpha-lactalbumin Alpha-L-iduronidase -- Transkaryotic Therapies, BioMarin alteplase -- Genentech alvircept sudotox - NIH

ALX-0600, a GLP-2 agonist -- NPS Allelix

#### **FIG. 28A**

Corp.

ALX1-11 -sNPS Pharmaceuticals Molecular Evolution Alzheimer's disease gene therapy Anti-angiogenesis monoclonal antibodies --AM-133 -- AMRAD KS Biomedix/Schering AG Amb a 1 immunostim conj. -- Dynavax Anti-B4 MAb-DC1 conjugate -- ImmunoGen AMD 3100 - AnorMED -- NIS Anti-B7 antibody PRIMATIZED -- IDEC AMD 3465 - AnorMED -- NIS AMD 3465 - AnorMED -- NIS Anti-B7-1 MAb 16-10A1 Anti-R7-1 MAb 1G10 AMD Fab -- Genentech Amediplase - Menarini, Novartis Anti-B7-2 MAb GL-1 Anti-B7-2-gelonin immunotoxin -AM-F9 Amoebiasis vaccine Antibacterials/antifungals --Diversa/IntraBiotics Amphiregulin -- Octagene Anti-beta-amyloid monoclonal antibodies -anakinra -- Amgen Cambridge Antibody Tech., Wyeth-Ayerst analgesic -- Nobex Anti-BLvS antibodies -- Cambridge ancestim -- Amgen Antibody Tech. /Human Genome Sciences AnergiX.RA - Corixa, Organon Antibody-drug conjugates -- Seattle Angiocidin -- InKine Genetics/Eos angiogenesis inhibitors -- ILEX Anti-C5 MAb BB5-1 -- Alexion AngioMab - Antisoma Angiopoietins -- Regeneron/Procter & Anti-C5 MAb N19-8 -- Alexion Anti-C8 MAb anticancer cytokines - BioPulse angiostatin -- EntreMed Angiostatin/endostatin gene therapy -anticancer matrix - Telios Integra Anticancer monoclonal antibodies - ARIUS. Genetix Pharmaceuticals angiotensin-II. topical -- Maret **Immunex** anticancer peptides - Maxygen, Micrologix Anthrax -- EluSys Therapeutics/US Army Medical Research Institute Anticancer prodrug Tech. -- Alexion Anthrax vaccine Antibody Technologies Anti platelet-derived growth factor D human anticancer Troy-Bodies - Affite -- Affitech anticancer vaccine -- NIH monoclonal antibodies - CuraGen Anti-17-1A MAb 3622W94 -anticancers -- Epimmune Anti-CCR5/CXCR4 sheep MAb -- KS GlaxoSmithKline Anti-2C4 MAb -- Genentech Biomedix Holdings anti-4-1BB monoclonal antibodies -- Bristol- Anti-CD11a MAb KBA --Myers Squibb Anti-CD11a MAb M17 Anti-Adhesion Platform Tech. -- Cytovax Anti-CD11a MAb TA-3 -Anti-adipocyte MAb -- Cambridge Antibody Anti-CD11a MAb WT.1 --Tech./ObeSvs Anti-CD11b MAb -- Pharmacia antiallergics -- Maxygen Anti-CD11b MAb LM2 antiallergy vaccine -- Acambis Anti-CD154 MAb -- Biogen Anti-alpha-4-integrin MAb Anti-CD16-anti-CD30 MAb -- Biotest

Anti-CD18 MAb -- Pharmacia Anti-CD4 MAb - Centocor, IDEC Pharmaceuticals, Xenova Group Anti-CD19 MAb B43 -Anti-CD19 MAb -liposomal sodium butyrate Anti-CD4 MAb 16H5 Anti-CD4 MAb 4162W94 - GlaxoSmithKline conjugate -Anti-CD4 MAb B-F5 -- Diaclone Anti-CD147 Anti-CD19 MAb-saporin conjugate -Anti-CD4 MAb GK1-5 Anti-CD19-dsFv-PE38-immunotoxin -Anti-CD4 MAb KT6 Anti-CD4 MAb OX38 Anti-CD2 MAb 12-15 --Anti-CD4 MAb PAP conjugate -- Bristol-Anti-CD2 MAb B-E2 -- Diaclone Myers Squibb Anti-CD2 MAb OX34 -Anti-CD4 MAb RIB 5-2 Anti-CD2 MAb OX54 -Anti-CD4 MAb W3/25 Anti-CD2 MAb OX55 -Anti-CD4 MAb YTA 3.1.2 Anti-CD2 MAb RM2-1 Anti-CD4 MAb YTS 177-9 Anti-CD2 MAb RM2-2 Anti-CD40 ligand MAb 5c8 -- Biogen Anti-CD2 MAb RM2-4 Anti-CD40 MAb Anti-CD20 MAb BCA B20 Anti-CD20-anti-Fc alpha RI bispecific MAb -Anti-CD40 MAb 5D12 - Tanox Anti-CD44 MAb A3D8 Medarex. Tenovus Anti-CD22 MAb-saporin-6 complex -Anti-CD44 MAb GKWA3 Anti-CD44 MAb IM7 Anti-CD3 immunotoxin -Anti-CD3 MAb 145-2C11 -- Pharming Anti-CD44 MAb KM81 Anti-CD44 variant monoclonal antibodies --Anti-CD3 MAb CD4lgG conjugate --Corixa/Hebrew University Genentech Anti-CD3 MAb humanised - Protein Design, Anti-CD45 MAb BC8-I-131 Anti-CD45RB MAb RW Johnson Anti-CD48 MAb HuLy-m3 Anti-CD3 MAb WT32 Anti-CD3 MAb-ricin-chain-A conjugate -Anti-CD48 MAb WM-63 Anti-CD3 MAb-xanthine-oxidase conjugate Anti-CD5 MAb -- Becton Dickinson Anti-CD5 MAb OX19 Anti-CD30 MAb BerH2 -- Medac Anti-CD6 MAb Anti-CD7 MAb-PAP conjugate Anti-CD30 MAb-saporin coniugate Anti-CD7 MAb-ricin-chain-A conjugate Anti-CD30-scFv-ETA'-immunotoxin Anti-CD8 MAb - Amerimmune, Cvtodyn, Anti-CD38 MAb AT13/5 Anti-CD38 MAb-saporin conjugate Becton Dickinson Anti-CD3-anti-CD19 bispecific MAb Anti-CD8 MAb 2-43 Anti-CD3-anti-EGFR MAb Anti-CD8 MAb OX8 Anti-CD3-anti-interleukin-2-receptor MAb Anti-CD80 MAb P16C10 -- IDEC Anti-CD80 MAb P7C10 -- ID Vaccine Anti-CD3-anti-MOv18 MAb -- Centocor Anti-CD3-anti-SCLC bispecific MAb Anti-CD8-idarubicin conjugate Anti-CD4 idiotype vaccine Anti-CEA MAb CE-25

Anti-CFA MAb MN 14 - Immunomedics

WO 2004/033651 PCT/US2003/031974

### 34/498

Anti-heparanase human monocional Anti-CEA MAb MN14-PE40 conjugate antibodies -- Oxford Immunomedics Anti-CEA MAb T84,66-interleukin-2 Glycosciences/Medarex Anti-hepatitis C virus human monoclonal conjugate antibodies -- XTL Biopharmaceuticals Anti-CEA sheep MAb -- KS Biomedix Anti-HER-2 antibody gene therapy Holdinas Anti-herpes antibody - Epicyte Anti-cell surface monoclonal antibodies --Anti-HIV antibody - Epicyte Cambridge Antibody Tech. /Pharmacia anti-HIV catalytic antibody -- Hesed Biomed Anti-c-erbB2-anti-CD3 bifunctional MAb -anti-HIV fusion protein -- Idun Otsuka anti-HIV proteins -- Cangene Anti-CMV MAb -- Scotgen Anti-HM1-24 MAb -- Chugai Anti-complement Anti-hR3 MAb Anti-CTLA-4 MAb Anti-Human-Carcinoma-Antigen MAb --Anti-EGFR catalytic antibody -- Hesed Riomed Epicyte Anti-ICAM-1 MAb -- Boehringer Ingelheim anti-FGFR immunotoxin -- IVAX Anti-ICAM-1 MAb 1A-29 - Pharmacia Anti-EGFR MAb -- Abgenix Anti-ICAM-1 MAb HA58 Anti-EGFR MAb 528 Anti-EGFR MAb KSB 107 -- KS Biomedix Anti-ICAM-1 MAb YN1/1.7.4 Anti-ICAM-3 MAb ICM3 -- ICOS Anti-EGFR MAb-DM1 conjugate --Anti-idiotype breast cancer vaccine 11D10 ImmunoGen Anti-idiotype breast cancer vaccine Anti-FGFR MAb-LA1 -ACA14C5 -Anti-EGFR sheep MAb -- KS Biomedix Anti-idiotype cancer vaccine -- ImClone Anti-FAP MAb F19-I-131 Systems/Merck KGaA ImClone, Viventia Anti-Fas IgM MAb CH11 Anti-Fas MAb Jo2 Biotech Anti-idiotype cancer vaccine 1A7 -- Titan Anti-Fas MAb RK-8 Anti-Fit-1 monoclonal antibodies -- ImClone Anti-idiotype cancer vaccine 3H1 -- Titan Anti-idiotype cancer vaccine TriAb -- Titan Anti-fungal peptides -- State University of Anti-idiotype Chlamydia trachomatis New York antifungal tripeptides - BTG vaccine Anti-ganglioside GD2 antibody-interleukin-2 Anti-idiotype colorectal cancer vaccine --Novartis fusion protein -- Lexigen Anti-idiotype colorectal cancer vaccine --Anti-GM2 MAb -- Kyowa Anti-GM-CSF receptor monoclonal Onvvax Anti-idiotype melanoma vaccine -- IDEC antibodies -- AMRAD Anti-gp130 MAb -- Tosoh **Pharmaceuticals** Anti-HCA monoclonal antibodies --Anti-idiotype ovarian cancer vaccine ACA AltaRex/Epigen Anti-hCG antibodies -- Abgenix/AVI Anti-idiotype ovarian cancer vaccine AR54 -- AltaRex BioPharma

Anti-L-selectin monoclonal antibodies --Anti-idiotype ovarian cancer vaccine CA-Protein Design Labs, Abgenix, Stanford 125 - AltaRex, Biomira Anti-IgE catalytic antibody - Hesed Biomed University Anti-MBL monoclonal antibodies --Anti-laE MAb E26 -- Genentech Alexion/Brigham and Women's Hospital Anti-IGF-1 MAb Anti-MHC monoclonal antibodies anti-inflammatory -- GeneMax Anti-MIF antibody humanised - IDEC, anti-inflammatory peptide -- BTG Cytokine PharmaSciences anti-integrin peptides -- Burnha Anti-interferon-alpha-receptor MAb 64G12 -- Anti-MRSA/VRSA sheep MAb -- KS Biomedix Holdings Pharma Pacific Management Anti-interferon-gamma MAb -- Protein Anti-mu MAb -- Novartis Anti-MUC-1 MAb Design Labs Anti-interferon-gamma polyclonal antibody - Anti-MUC 18 - Advanced Biotherapy Anti-Nogo-A MAb IN1 Anti-nuclear autoantibodies -- Procyon Anti-interleukin-10 MAb -Anti-ovarian cancer monoclonal antibodies -Anti-interleukin-12 MAb -Anti-interleukin-1-beta polyclonal antibody -- - Dompe Anti-p185 monoclonal antibodies R&D Systems Anti-p43 MAb Anti-interleukin-2 receptor MAb 2A3 Antiparasitic vaccines Anti-interleukin-2 receptor MAb 33B3-1 --Anti-PDGF/bFGF sheep MAb -- KS Immunotech Biomedix Anti-interleukin-2 receptor MAb ART-18 Anti-properdin monoclonal antibodies --Anti-interleukin-2 receptor MAb LO-Tact-1 Abgenix/Gliatech Anti-interleukin-2 receptor MAb Mikbeta1 Anti-PSMA (prostrate specific membrane Anti-interleukin-2 receptor MAb NDS61 Anti-interleukin-4 MAb 11B11 antigen) Anti-interleukin-5 MAb -- Wallace Anti-PSMA MAb J591 -- BZL Biologics Anti-Rev MAb gene therapy -Laboratories Anti-RSV antibodies - Epicyte, Intracell Anti-interleukin-6 MAb - Centocor, Anti-RSV monoclonal antibodies --Diaclone, Pharmadigm Anti-interleukin-8 MAb -- Abgenix Medarex/MedImmune, Applied Molecular Evolution/MedImmune Anti-interleukin-8 MAb - Xenotech Anti-RSV MAb, inhalation --Anti-. II 1 MAh Anti-Klebsiella sheep MAb -- KS Biomedix Alkermes/MedImmune Anti-RT gene therapy Holdings Antisense K-ras RNA gene therapy Anti-Laminin receptor MAb-liposomal Anti-SF-25 MAb doxorubicin conjugate Anti-LCG MAb -- Cytoclonal Anti-sperm antibody -- Epicyte Anti-Tac(Fv)-PE38 conjugate Anti-lipopolysaccharide MAb -- VitaResc Anti-TAPA/CD81 MAb AMP1

Anti-tat gene therapy

Anti-TCR-alphabeta MAb H57-597 Anti-TCR-alphabeta MAb R73 Anti-tenascin MAb BC-4-I-131 Anti-TGF-beta human monoclonal antibodies -- Cambridge Antibody Tech., Genzyme Anti-TGF-beta MAb 2G7 -- Genentech Antithrombin III -- Genzyme Transgenics, Aventis, Bayer, Behringwerke, CSL, Myriad Anti-Thv1 MAb Anti-Thv1.1 MAb Anti-tissue factor/factor VIIA sheep MAb --KS Biomedix Anti-TNF monoclonal antibodies -Centocor, Chiron, Peptech, Pharacia, Anti-TNF sheep MAb - KS Biomedix Holdings Anti-TNFalpha MAb -- Genzyme Anti-TNFalpha MAb B-C7 -- Diaclone Anti-tooth decay MAb -- Planet BioTech. Anti-TRAIL receptor-1 MAb -- Takeda Antitumour RNases -- NIH Anti-VCAM MAb 2A2 - Alexion Anti-VCAM MAb 3F4 - Alexion Anti-VCAM-1 MAb Anti-VEC MAb -- ImClone Anti-VEGF MAb -- Genentech Anti-VEGE MAb 2C3 Anti-VEGF sheep MAb -- KS Biomedix Holdings Anti-VLA-4 MAb HP1/2 -- Biogen Anti-VI A-4 MAh PS/2 Anti-VLA-4 MAb R1-2 Anti-VLA-4 MAb TA-2 Anti-VAP-1 human MAb Anti-VRE sheep MAb -- KS Biomedix Holdings ANUP -- TranXenoGen ANUP-1 -- Pharis

AOP-RANTES -- Senetek Apan-CH - Praecis Pharmaceuticals APC-8024 -- Demegen ApoA-1 -- Milano, Pharmacia Apogen -- Alexion apolipoprotein A1 -- Avanir Apolipoprotein E -- Bio-Tech. General Applaggin - Biogen aprotinin -- ProdiGene APT-070C - AdProTech AR 177 -- Aronex Pharmaceuticals AR 209 -- Aronex Pharmaceuticals, **Antigenics** AR545C ARGENT gene delivery systems - ARIAD Arresten ART-123 -- Asahi Kasei arvisulfatase B -- BioMarin Arylsulfatase B, Recombinant human --**BioMarin** AS 1051 -- Aiinomoto ASI-BCL -- Intracell Asparaginase - Merck ATL-101 - Alizyme Atrial natriuretic peptide -- Pharis Aurintricarboxylic acid-high molecular weiaht Autoimmune disorders -- GPC Biotech/MorphoSvs Autoimmune disorders and transplant rejection -- Bristol-Myers Squibb/Genzyme Tra Autoimmune disorders/cancer --Abgenix/Chiron, CuraGen Autotaxin -Avicidin - NeoRx axogenesis factor-1 -- Boston Life Sciences Axokine -- Regeneron B cell lymphoma vaccine -- Biomira B7-1 gene therapy -BABS proteins -- Chiron

RMP 2 -- Genetics Institute/Medtronic-BAM-002 -- Novelos Therapeutics Sofamor Danek, Genetics Institute/ Basiliximab (anti CD25 MAb) -- Novartis Collagenesis, Genetics Bay-16-9996 -- Bayer Institute/Yamanouch Bay-39-9437 -- Bayer BMP 2 gene therapy Bay-50-4798 -- Bayer BMP 52 -- Aventis Pasteur, Biopharm BB-10153 -- British Biotech RMP-2 -- Genetics Institute BBT-001 -- Bolder BioTech. BMS 182248 -- Bristol-Myers Squibb BBT-002 -- Bolder BioTech. BMS 202448 - Bristol-Myers Squibb BRT-003 -- Bolder BioTech. bone growth factors -- IsoTis BBT-004 -- Bolder BioTech. BPC-15 -- Pfizer BRT-005 -- Bolder BioTech. brain natriuretic peptide -BBT-006 -- Bolder BioTech. Breast cancer -- Oxford BBT-007 -- Bolder BioTech. GlycoSciences/Medarex BCH-2763 -- Shire Breast cancer vaccine -- Therion Biologics. BCSF -- Millenium Biologix BDNF -- Regeneron - Amgen Oregon Becaplermin -- Johnson & Johnson, Chiron BSSL -- PPL Therapeutics BST-2001 – BioStratum Bectumomab - Immunomedics BST-3002 -- BioStratum Beriplast -- Aventis BTI 322 -Beta-adrenergic receptor gene therapy -butvrvlcholinesterase - Shire University of Arkansas C 6822 -- COR Therapeutics bFGF -- Scios C1 esterase inhibitor -- Pharming BI 51013 - Behringwerke AG C3d adjuvant -- AdProTech BIBH 1 -- Boehringer Ingelheim CAB-2.1 -- Millennium BIM-23190 - Beaufour-Ipsen calcitonin - Inhale Therapeutics Systems, birch pollen immunotherapy -- Pharmacia Aventis, Genetronics, TranXenoGen. bispecific fusion proteins -- NIH Unigene, Rhone Poulenc Rohrer Bispecific MAb 2B1 - Chiron calcitonin -- oral - Nobex, Emisphere. Bitistatin Pharmaceutical Discovery BIWA 4 -- Boehringer Ingelheim Calcitonin gene-related peptide -- Asahi blood substitute - Northfield, Baxter Intl. BI P-25 -- Biomira Kasei - Unigene BLS-0597 -- Boston Life Sciences calcitonin, human -- Suntory calcitonin, nasal - Novartis, Unigene BLvS -- Human Genome Sciences calcitonin, Panoderm - Elan BLvS radiolabelled -- Human Genome calcitonin, Peptitrol -- Shire Sciences calcitonin, salmon -- Therapicon BM 06021 -- Boehringer Mannheim calin -- Biopharm BM-202 -- BioMarin Calphobindin I BM-301 -- BioMarin calphobindin I -- Kowa BM-301 -- BioMarin calreticulin -- NYU BM-302 -- BioMarin

WO 2004/033651 PCT/US2003/031974

38/498

CD4 fusion toxin -- Senetek Campath-1G CD4 IgG -- Genentech Campath-1M CD4 receptor antagonists -cancer therapy -- Cangene Pharmacopeia/Progenics cancer vaccine - Aixlie, Aventis Pasteur, CD4 soluble -- Progenics Center of Molecular Immunology, YM CD4. soluble -- Genzyme Transgenics BioSciences, Cytos, Genzyme, CD40 ligand -- Immunex Transgenics, Globelmmune, Igeneon, CD4-ricin chain A -- Genentech ImClone, Virogenetics, InterCell, Iomai, CD59 gene therapy -- Alexion Jenner Biotherapies, Memorial Sloan-Kettering Cancer Center, Sydney Kimmel CD8 TIL cell therapy -- Aventis Pasteur CD8. soluble -- Avidex Cancer Center, Novavax, Protein CD95 ligand -- Roche Sciences, Argonex, SIGA CDP 571 -- Celltech Cancer vaccine ALVAC-CEA B7.1 -CDP 850 -- Celltech Aventis Pasteur/Therion Biologics CDP-860 (PEG-PDGF MAb) -- Celltech Cancer vaccine CEA-TRICOM -- Aventis CDP 870 -- Celltech Pasteur/Therion Biologics CDS-1 -- Ernest Orlando Cancer vaccine gene therapy -- Cantab Cedelizumab -- Ortho-McNeil **Pharmaceuticals** Cancer vaccine HER-2/neu - Corixa Cetermin -- Insmed CETP vaccine -- Avant Cancer vaccine THERATOPE -- Biomira Cetrorelix cancer vaccine, PolyMASC - Valentis Cetuximab Candida vaccine - Corixa, Inhibitex CGH 400 -- Novartis Canstatin -- ILEX CGP 42934 - Novartis CAP-18 - Panorama CGP 51901 - Tanox Cardiovascular gene therapy -- Collateral CGRP -- Unigene Therapeutics CGS 27913 - Novartis carperitide -- Suntory CGS 32359 -- Novartis Casocidin-1 -- Pharis CAT 152 - Cambridge Antibody Tech. Chagas disease vaccine -- Corixa chemokines - Immune Response CAT 192 -- Cambridge Antibody Tech. CAT 213 -- Cambridge Antibody Tech. CHH 380 -- Novartis chitinase - Genzyme, ICOS Catalase-- Enzon Chlamydia pneumoniae vaccine -- Antex Cat-PAD -- Circassia CB 0006 -- Celltech Biologics Chlamydia trachomatis vaccine -- Antex CCK(27-32)-- Akzo Nobel CCR2-64I -- NIH Biologics Chlamydia vaccine -- GlaxoSmithKline CD. Procept -- Paligent Cholera vaccine CVD 103-HqR -- Swiss CD154 gene therapy Serum and Vaccine Institute Berne CD39 -- Immunex Cholera vaccine CVD 112 -- Swiss Serum CD39-L2 -- Hvseq CD39-L4 -- Hyseq and Vaccine Institute Berne

FIG. 28H

WO 2004/033651 PCT/US2003/031974

## 39/498

Cholera vaccine inactivated oral - SBL CRL 1605 -- CytRx CS-560 -- Sankyo Vaccin CSF -- ZymoGenetics Chrysalin -- Chrysalis BioTech. CSF-G - Hangzhou, Dong-A, Hanmi CI-782 -- Hitachi Kase CSF-GM - Cangene, Hunan, LG Chem Ciliary neurotrophic factor - Fidia, Roche CSF-M -- Zarix CIM project -- Active Biotech CT 1579 - Merck Frosst CL 329753 -- Wyeth-Ayerst CT 1786 - Merck Frosst CL22. Cobra -- ML Laboratories CT-112<sup>^</sup> -- BTG Clenoliximab -- IDEC CTB-134L -- Xenova Clostridium difficile antibodies -- Epicyte CTC-111 -- Kaketsuken clotting factors -- Octagene CTGF -- FibroGen CMB 401 -- Celltech CTLA4-la -- Bristol-Myers Squibb CNTF -- Sigma-Tau CTLA4-lg gene therapy -Cocaine abuse vaccine - Cantab, CTP-37 -- AVI BioPharma ImmuLogic, Scripps C-type natriuretic peptide -- Suntory coccidiomycosis vaccine -- Arizo CVS 995 - Corvas Intl. collagen -- Type I -- Pharming Collagen formation inhibitors -- FibroGen CX 397 – Nikko Kyodo Collagen/hydroxyapatite/bone growth factor CY 1747 -- Epimmune CY 1748 -- Epimmune -- Aventis Pasteur, Biopharm, Orquest Cyanovirin-N collagenase -- BioSpecifics Colorectal cancer vaccine -- Wistar Institute Cystic fibrosis therapy -- CBR/IVAX Component B, Recombinant -- Serono CYT 351 Connective tissue growth factor inhibitors - cytokine Traps - Regeneron cytokines - Enzon, Cytoclonal FibroGen/Taisho Cytomegalovirus glycoprotein vaccine -Contortrostatin Chiron, Aquila Biopharmaceuticals. contraceptive vaccine - Zonagen Aventis Pasteur, Virogenetics Contraceptive vaccine hCG Cytomegalovirus vaccine live -- Aventis Contraceptive vaccine male reversible --Pasteur IMMUCON Cytosine deaminase gene therapy --Contraceptive vaccine zona pellucida --GlaxoSmithKline Zonagen Copper-64 labelled MAb TETA-1A3 - NCI DA-3003 -- Dong-A DAB389interleukin-6 -- Senetek Coralyne DAB389interleukin-7 Corsevin M DAC:GLP-2 -- ConjuChem, Inc. C-peptide analogues -- Schwarz Daclizumab (anti-IL2R MAb) - Protein CPI-1500 -- Consensus Design Labs CRF -- Neurobiological Tech. DAMP<sup>A</sup> -- Incvte Genomics cRGDfV pentapeptide -Daniplestim -- Pharmacia CRL 1095 -- CvtRx darbepoetin alfa - Amgen CRL 1336 -- CvtRx

dural graft matrix -- Integra DBI-3019 -- Diabetogen Duteplase - Baxter Intl. DCC -- Genzyme DWP-401 -- Daewoong DDF -- Hysea DWP-404 -- Daewoong decorin - Integra, Telios DWP-408 -- Daewoong defensins - Large Scale Biology Dx 88 (Epi-KAL2) -- Dyax DEGR-VIIa Dx 890 (elastin inhibitors) -- Dyax Delmmunised antibody 3B6/22 AGEN Deimmunised anti-cancer antibodies -F coli O157 vaccine -- NIH E21-R -- BresaGen Biovation/Viragen Eastern equine encephalitis virus vaccine -Dendroamide A Dengue vaccine -- Bavarian Nordic, Merck Echicetin --Echinhibin 1 denileukin diftitox -- Ligand Echistatin -- Merck DES-1101 -- Desmos Echitamine desirudin -- Novartis Ecromeximab - Kyowa Hakko desmopressin -- Unigene EC-SOD -- PPL Therapeutics Desmoteplase - Merck, Schering AG Eculizumab (5G1.1) -- Alexion Destabilase Diabetes gene therapy - DeveloGen, Pfizer EDF - Ajinomoto FDN derivative -- NIH Diabetes therapy -- Crucell Diabetes type 1 vaccine -- Diamyd FDNA -- NIH Edobacomab -- XOMA Therapeutics DiaCIM -- YM BioSciences Edrecolomab -- Centocor FF 5077 dialytic oligopeptides - Research Corp Ffalizumab -- Genentech Diamyd -- Diamyd Therapeutics EGF fusion toxin - Seragen, Ligand DiaPep227-- Pepgen EGF-P64k vaccine -- Center of Molecular DiavaX -- Corixa Digoxin MAb -- Glaxo Immunology Diphtheria tetanus pertussis-hepatitis B EL 246 -- LigoCyte elastase inhibitor -- Synergen vaccine -- GlaxoSmithKline elcatonin -- Therapicon DIR therapy -- Solis Therapeutics -EMD 72000 - Merck KGaA DNase -- Genentech Dornase alfa -- Genentech Fmdogain -- BIORA emfilermin -- AMRAD Domase alfa, inhalation -- Genentech Doxorubicin-anti-CEA MAb conjugate -Fmoctakin -- Novartis enamel matrix protein -- BIORA Immunomedics DP-107 -- Trimeris Fndo III -- NYU endostatin - EntreMed, Pharis drotrecogin alfa -- Eli Lilly DTctGMCSF Enhancins -- Micrologix Enlimomab -- Isis Pharm. DTP-polio vaccine - Aventis Pasteur Enoxaparin sodium -- Pharmuka DU 257-KM231 antibody conjugate --

Kvowa

WO 2004/033651 PCT/US2003/031974

41/498

Factor IX gene therapy -- Cell Genesys enzyme linked antibody nutrient depletion Factor VII -- Novo Nordisk, Bayer, Baxter therapy -- KS Biomedix Holdings Eosinophil-derived neutralizing agent -Intl. Factor VIIa -- PPL Therapeutics, EP-51216 -- Asta Medica ZvmoGenetics FP-51389 -- Asta Medica Factor VIII - Bayer Genentech, Beaufour-EPH family ligands -- Regeneron Ipsen, CLB, Inex, Octagen, Pharmacia, Epidermal growth factor -- Hitachi Kasei, Pharming Johnson & Johnson Factor VIII -- PEGylated -- Baver Epidermal growth factor fusion toxin --Factor VIII fragments -- Pharmacia Senetek Factor VIII gene therapy -- Targeted Epidermal growth factor-genistein -Genetics EPI-HNE-4 -- Dyax Factor VIII sucrose formulation - Baver. EPI-KAL2 -- Dyax Epoetin-alfa - Amgen, Dragon Genentech Factor VIII-2 -- Bayer Pharmaceuticals, Nanjing Huaxin Factor VIII-3 -- Bayer Epratuzumab - Immunomedics Factor Xa inhibitors - Merck, Novo Nordisk, Fostein-Barr virus vaccine --Mochida Aviron/SmithKline Beecham, Bioresearch Factor XIII -- ZymoGenetics Eptacog alfa -- Novo Nordisk Factors VIII and IX gene therapy -- Genetics Eptifibatide -- COR Therapeutics Institute/Targeted Genetics erb-38 -Famoxin -- Genset Frlizumab -- Genentech erythropoietin -- Alkermes, ProLease, Dong-Fas (delta) TM protein - LXR BioTech. Fas TR -- Human Genome Sciences A. Elanex, Genetics Institute, LG Chem, Felvizumab -- Scotgen Protein Sciences, Serono, Snow Brand, FFR-VIIa - Novo Nordisk SRC VB VECTOR, Transkaryotic FG-001 - F-Gene Therapies FG-002 - F-Gene Erythropoietin Beta -- Hoffman La Roche Erythropoietin/Epoetin alfa -- Chugai FG-004 - F-Gene Escherichia coli vaccine -- North American FG-005 - F-Gene FGF + fibrin -- Repair Vaccine, SBL Vaccin, Swiss Serum and Fibrimage -- Bio-Tech. General Vaccine Institute Berne fibrin-binding peptides - ISIS Innovation etanercept -- Immunex fibringen -- PPL Therapeutics, Pharming examorelin – Mediolanum fibroblast growth factor - Chiron, NYU. Exendin 4 -- Amylin Ramot, ZymoGenetics exonuclease VII fibrolase conjugate - Schering AG F 105 - Centocor F-992 -- Fornix Filarastim -- Amaen filgrastim -- PDA modified -- Xencor Factor IX -- Alpha Therapeutics, Welfide FLT-3 ligand - Immunex Corp., CSL, enetics Institute/AHP,

Pharmacia, PPL Therapeutics

FN18 CRM9 -

follistatin -- Biotech Australia, Human Therapeutics follitropin alfa - Alkermes, ProLease, PowderJect, Serono, Akzo Nobel Follitropin Beta - Bayer, Organon FP 59 FSH -- Ferring FSH + LH -- Ferring F-spondin -- CeNeS fusion protein delivery system -- UAB Research Foundation fusion toxins - Boston Life Sciences G 5598 -- Genentech GA-II - Transkarvotic Therapies Gamma-interferon analogues -- SRC VB VECTOR Ganirelix -- Roche gastric lipase -- Meristem Gavilimomab -G-CSF - Amgen, SRC VB VECTOR GDF-1 -- CeNeS GDF-5 -- Biopharm GDNF (glial derived neurotrophic factor) -Amaen aelsolin -- Biogen Gemtuzumab ozogamicin - Celltech Gene-activated epoetin-alfa -- Aventis Pharma - Transkaryotic Therapies Glatiramer acetate -- Yeda glial growth factor 2 -- CeNeS GLP-1 - Amylin, Suntory, TheraTech, Watson GLP-1 peptide analogues - Zealand Pharaceuticals GLP-2 - Novo Nordisk, Ontario, Inc., Suntory Limited glucagon -- Eli Lilly, ZymoGenetics Glucagon-like peptide-1 7-36 amide --Suntory Glucogen-like peptide -- Amylin

Glucocerebrosidase -- Genzvme glutamate decarboxylase -- Genzyme Transgenics Glycoprotein S3 -- Kureha GM-CSF -- Immunex GM-CSF tumour vaccine -- PowderJect GnRH immunotherapeutic -- Protherics Goserelin (LhRH antagonist) -- AstraZeneca gp75 antigen - ImClone an96 -- Antigenics GPI 0100 -- Galenica GR 4991W93 -- GlaxoSmithKline Granulocyte colony-stimulating factor --Dong-A Granulocyte colony-stimulating factor conjugate grass allergy therapy -- Dynavax GRF1-44 -- ICN Growth Factor - Chiron, Atrigel, Atrix, Innogenetics, ZymoGenetics, Novo growth factor peptides -- Biotherapeutics growth hormone -- LG Chem growth hormone, Recombinant human --GT 4086 -- Gliatech GW 353430 -- GlaxoSmithKline GW-278884 -- GlaxoSmithKline H 11 -- Viventia Biotech Glanzmann thrombasthenia gene therapy - H5N1 influenza A virus vaccine -- Protein Sciences haemoglobin -- Biopure haemoglobin 3011, Recombinant -- Baxter Healthcare haemoglobin crosfumaril – Baxter Intl. haemoglobin stabilized -- Ajinomoto haemoglobin, recombinant -- Apex HAF -- Immune Response Hantavirus vaccine HB 19 HBNF -- Regeneron

HCC-1 -- Pharis

hCG -- Milkhaus hCG vaccine -- Zonagen HF-317 -- Hollis-Eden Pharmaceuticals Heat shock protein cancer and influenza vaccines - StressGen Helicobacter pylori vaccine - Acambis, AstraZeneca/CSL, Chiron, Provalis Helistat-G - GalaGen Hemolink -- Hemosol hepapoietin -- Snow Brand heparanase -- InSight heparinase I -- Ibex heparinase III -- Ibex Hepatitis A vaccine -- American Biogenetic HIP-- Altachem Sciences Hepatitis A vaccine inactivated Henatitis A vaccine Nothay - Chiron Henatitis A-hepatitis B vaccine --GlaxoSmithKline hepatitis B therapy -- Tripep Henatitis B vaccine - Amgen, Chiron SpA, Meiji Milk, NIS, Prodeva, PowderJect, Rhein Biotech Henatitis B vaccine recombinant -- Evans Vaccines, Epitec Combiotech, Genentech, Medlmmune, Merck Sharp & Dohme, Rhein Biotech, Shantha Biotechnics, Vector, Yeda Hepatitis B vaccine recombinant TGP 943 - HIV immune globulin - Abbott, Chiron Takeda Hepatitis C vaccine -- Bavarian Nordic. Chiron, Innogenetics Acambis, Hepatitis D vaccine -- Chiron Vaccines Henatitis E vaccine recombinant --

Sosei hepatocyte growth factor kringle fragments -- EntreMed

Genelabs/GlaxoSmithKline, Novavax hepatocyte growth factor - Panorama,

Her-2/Neu peptides -- Corixa

Herpes simplex glycoprotein DNA vaccine -Merck, Wyeth-Lederle Vaccines-Malvern, Genentech, GlaxoSmithKline, Chiron, Takeda

Herpes simplex vaccine -- Cantab Pharmaceuticals, CEL-SCI, Henderson Morley

Herpes simplex vaccine live -- ImClone Systems/Wyeth-Lederle, Aventis Pasteur HGF derivatives - Dompe hIAPP vaccine -- Crucell Hib-hepatitis B vaccine -- Aventis Pasteur

HIC 1 Hirudins - Biopharma, Cangene, Dongkook, Japan Energy Corporation, Pharmacia Corporation, SIR International, Sanofi-Synthelabo, Sotragene, Rhein Biotech HIV edible vaccine -- ProdiGene HIV ap120 vaccine - Chiron, Ailnomoto, GlaxoSmithKline, ID Vaccine, Progenics, VaxGen HIV gp120 vaccine gene therapy -HIV ap160 DNA vaccine - PowderJect. Aventis Pasteur, Oncogen, Hyland Immuno. Protein Sciences HIV gp41 vaccine -- Panacos HIV HGP-30W vaccine -- CEL-SCI

HIV peptides -- American Home Products HIV vaccine -- Applied bioTech., Axis Genetics, Biogen, Bristol-Myers Squibb, Genentech, Korea Green Cross, NIS, Oncogen, Protein Sciences Corporation, Terumo, Tonen Corporation, Wyeth-Averst, Wyeth-Lederle Vaccines-Malvern, Advanced BioScience Laboratories. Bavarian Nordic, Bavarian Nordic/Statens

Serum Institute, GeneCure, Immune Response, Progenics, Therion Biologics, United Biomedical. Chiron

# FIG. 28M

HIV vaccine vCP1433 -- Aventis Pasteur HIV vaccine vCP1452 -- Aventis Pasteur HIV vaccine vCP205 -- Aventis Pasteur HL-9 -- American BioScience HM-9239 - Cytran HML-103 -- Hemosol HML-104 -- Hemosol HMI -105 -- Hemosol HMI -109 -- Hemosol HMI -110 -- Hemosol HMI -121 -- Hemosol hNLP -- Pharis Hookworm vaccine host-vector vaccines -- Henogen HPM 1 -- Chugai HPV vaccine -- MediGene HSA -- Meristem HSF -- StressGen HSP carriers -Weizmann, Yeda, Peptor HSPPC-70 -- Antigenics HSV 863 -- Novartis HTI V-I DNA vaccine HTLV-I vaccine HTI V-II vaccine -- Access HU 901 - Tanox Hu23F2G -- ICOS HuHMFG1 Humal YM -- Intracell Human krebs statika -- Yamanouchi human monoclonal antibodies --Abgenix/Biogen, Abgenix/ Corixa, Abgenix/Immunex, Abgenix/Lexicon, Abgenix/ Pfizer, Athersys/Medarex, Biogen/MorphoSys, CAT/Searle. Centocor/Medarex, Corixa/Kirin Brewery, Corixa/Medarex, Eos BioTech./Medarex, Fos/Xenerex, Exelixis/Protein Design Labs, ImmunoGen/ Raven, Medarex/ B.Twelve, MorphoSys/ImmunoGen, XTL Biopharmaceuticals/Dyax,

Human monoclonal antibodies --Medarex/Northwest Biotherapeutics. Medarex/Seattle Genetics human netrin-1 -- Exelixis human papillomavirus antibodies - Epicyte Human papillomavirus vaccine - Biotech Australia, IDEC, StressGen Human papillomavirus vaccine MEDI 501 --MedImmune/GlaxoSmithKline Human papillomavirus vaccine MEDI 503/MEDI 504 --MedImmune/GlaxoSmithKline Human papillomavirus vaccine TA-CIN -Cantab Pharmaceuticals Human papillomavirus vaccine TA-HPV --Cantab Pharmaceuticals Human papillomavirus vaccine TH-GW --Cantab/GlaxoSmithKline human polyclonal antibodies -- Biosite/Eos BioTech./ Medarex HSPPC-96, pathogen-derived -- Antigenics human type II anti factor VIII monoclonal antibodies -- ThromboGenics humanised anti glycoprotein Ib murine monoclonal antibodies -- ThromboGenics HumaRAD -- Intracell HuMax EGFR -- Genmab HuMax-CD4 -- Medarex HuMax-IL15 -- Genmab HYB 190 -- Hybridon HYB 676 -- Hybridon I-125 MAb A33 -- Celltech Ibritumomab tiuxetan -- IDEC IBT-9401 -- Ibex IBT-9402 -- Ibex IC 14 -- ICOS Idarubicin anti-Ly-2.1 -IDEC 114 -- IDEC IDEC 131 -- IDEC IDEC 152 -- IDEC IDM 1 -- IDM

IDPS -- Hollis-Eden Pharmaceuticals

iduronate-2-sulfatase -- Transkaryotic Therapies IGF/IBP-2-13 - Pharis IGN-101 -- Igeneon IK HIR02 – Iketon IL-11 -- Genetics Institute/AHP IL-13-PE38 -- NeoPharm IL-17 receptor -- Immunex IL-18BP -- Yeda IL-1Hv1 -- Hvseq IL-1ß -- Celltech IL-1ß adjuvant -- Celltech IL-2 -- Chiron IL-2 + IL-12 -- Hoffman La-Roche IL-6/sIL-6R fusion - Hadasit IL-6R derivative - Tosoh IL-7-Dap 389 fusion toxin - Ligand IL-21 - Novo Nordisk, ZymoGenetics IM-862 -- Cytran IMC-1C11 -- ImClone imiglucerase -- Genzyme Immune globulin intravenous (human) --Hoffman La Roche immune privilege factor -- Proneuron Immunocal -- Immunotec Immunogene therapy - Briana Bio-Tech Immunoliposomal 5-fluorodeoxyuridinedipalmitate immunosuppressant vaccine -- Aixlie immunotoxin - Antisoma, NIH ImmuRAIT-Re-188 - Immunomedics imreg-1 - Imreg infertility - Johnson & Johnson, E-TRANS Infliximab -- Centocor Influenza virus vaccine -- Aventis Pasteur. Protein Sciences inhibin -- Biotech Australia, Human Therapeutics Inhibitory G protein gene therapy INKP-2001 -- InKine

Inclimomab -- Diaclone

insulin -- AutoImmune, Altea, Biobras, BioSante, Bio-Tech. General, Chong Kun Dang, Emisphere, Flamel, Provalis, Rhein Biotech, TranXenoGen insulin (bovine) -- Novartis insulin analogue -- Eli Lilly Insulin Aspart -- Novo Nordisk insulin detemir - Novo Nordisk insulin alargine -- Aventis insulin inhaled - Inhale Therapeutics Systems, Alkermes insulin oral -- Inovax insulin, AeroDose -- AeroGen insulin, AERx -- Aradigm insulin, BEODAS -- Elan insulin, Biphasix -- Helix insulin, buccal -- Generex insulin, I2R - Flemington insulin, intranasal -- Bentley insulin, oral - Nobex, Unigene insulin. Orasome -- Endorex insulin, ProMaxx -- Epic insulin, Quadrant -- Elan insulin, recombinant -- Aventis insulin, Spiros -- Elan insulin. Transfersome -- IDEA insulin, Zvmo, recombinant - Novo Nordisk insulinotropin -- Scios Insulvsin gene therapy integrin antagonists -- Merck interferon (Alpha2) -- SRC VB VECTOR, Viragen, Dong-A, Hoffman La-Roche. Genentech interferon - BioMedicines, Human Genome Sciences interferon (Alfa-n3)-Interferon Sciences interferon (Alpha), Biphasix -- Helix

interferon (Alpha)-Amgen, BioNative, Novartis, Genzyme Transgenics, Havashibara, Inhale Therapeutics Systems, Medusa, Flamel, Dong-A, GeneTrol, Nastech, Shantha, Wassermann, LG Chem, Sumitomo, Aventis, Behring EGIS, Pepgen, Servier, Rhein Biotech, interferon (Alpha2A) interferon (Alpha2B) - Enzon, Schering-Plough, Biogen, IDEA interferon (Alpha-N1) -- GlaxoSmithKline interferon (beta) - Rentschler, GeneTrol, Meristem, Rhein Biotech, Toray, Yeda, Dajichi, Mochida interferon (Beta1A) - Serono, Biogen interferon (beta1A), inhale - Biogen interferon (ß1b)-- Chiron interferon (tau) -- Pepgen Interferon alfacon-1 -- Amgen Interferon alpha-2a vaccine Interferon Beta 1b -- Schering/Chiron, InterMune Interferon Gamma -- Boehringer Ingelheim, Sheffield, Rentschler, Hayashibara interferon receptor, Type I -- Serono interferon(Gamma1B) -- Genentech Interferon-alpha-2b + ribavirin - Biogen, ICN Interferon-alpha-2b gene therapy --Schering-Plough Interferon-con1 gene therapy interleukin-1 antagonists - Dompe Interleukin-1 receptor antagonist - Abbott Bioresearch, Pharmacia Interleukin-1 receptor type I -- Immunex interleukin-1 receptor Type II -- Immunex Interleukin-1 trap -- Regeneron Interleukin-1-alpha -- Immunex/Roche interleukin-2 -- SRC VB VECTOR. Aiinomoto, Biomira, Chiron

IL-2/ diphtheria toxin -- Ligand Interleukin-3 -- Cangene Interleukin-4 -- Immunology Ventures, Sanofi Winthrop, Schering-Plough, Immunex/ Sanofi Winthrop, Bayer, Ono interleukin-4 + TNF-Alpha -- NIH interleukin-4 agonist - Bayer interleukin-4 fusion toxin -- Ligand Interleukin-4 receptor - Immunex, Immun Interleukin-6 - Ajinomoto, Cangene, Yeda, Genetics Institute, Novartis interleukin-6 fusion protein interleukin-6 fusion toxin - Ligand, Serono interleukin-7 -- IC Innovations interleukin-7 receptor -- Immunex interleukin-8 antagonists -- Kyowa Hakko/Millennium/Pfizer interleukin-9 antagonists -- Genaera Interleukin-10 - DNAX, Schering-Plough Interleukin-10 gene therapy interleukin-12 -- Genetics Institute, Hoffman La-Roche interleukin-13 - Sanofi interleukin-13 antagonists -- AMRAD Interleukin-13-PE38QQR interleukin-15 -- Immunex interleukin-16 -- Research Corp interleukin-18 -- GlaxoSmithKline Interleukin-18 binding protein -- Serono lor-P3 -- Center of Molecular Immunology IP-10 -- NIH IPF -- Metabolex IR-501 -- Immune Response ISIS 9125 -- Isis Pharmaceuticals ISURF No. 1554 -- Millennium ISURF No. 1866 - Iowa State Univer. ITF-1697 -- Italfarmaco IxC 162 - Ixion J 695 - Cambridge Antibody Tech., Genetics Inst., Knoll

Jagged + FGF -- Repair

JKC-362 Phoenix Pharmaceuticals	leptin, 2nd-generation Amgen
JTP-2942 - Japan Tobacce	leridistim Pharmacia
Juman monoclonal antibodies	leuprolide, ProMaxx Epic
Medarex/Raven	leuprorelin, oral Unigene
K02 Axys Pharmaceuticals	LeuTech - Papatin
Keliximab IDEC	LEX 032 SuperGen
Keyhole limpet haemocyanin	LIDEPT Novartis
KGF Amgen	Lintuzumab (anti-CD33 MAb) Protein
KM 871 Kyowa	Design Labs
KPI 135 Scios	lipase Altus Biologics
KPI-022 Scios	lipid A vaccine - EntreMed
Kringle 5	lipid-linked anchor Tech ICRT, ID
KSB 304	Biomedical
KSB-201 KS Biomedix	liposome-CD4 Tech Sheffield
L 696418 Merck	Listeria monocytogenes vaccine
L 703801 Merck	LMB 1
L1 Acorda	LMB 7
L-761191 - Merck	LMB 9 Battelle Memorial Institute, NIH
lactoferrin - Meristem, Pharming, Agennix	LM-CD45 Cantab Pharmaceuticals
lactoferrin cardio Pharming	Iovastatin Merck
LAG-3 Serono	LSA-3
LAIT GEMMA	LT-ß receptor Biogen
LAK cell cytotoxin Arizona	lung cancer vaccine Corixa
lamellarins PharmaMar/University of	lusupultide Scios
Malaga	L-Vax AVAX
laminin A peptides NIH	LY 355455 Eli Lilly
lanoteplase Genetics Institute	LY 366405 Eli Lilly
laronidase BioMarin	LY-355101 Eli Lilly
Lassa fever vaccine	Lyme disease DNA vaccine Vical/Aventis
LCAT NIH	Pasteur
LDP 01 Millennium	Lyme disease vaccine Aquila
LDP 02 - Millennium	Biopharmaceuticals, Aventis, Pasteur,
Lecithinized superoxide dismutase -	Symbicom, GlaxoSmithKline, Hyland
Seikagaku	Immuno, MedImmune
LeIF adjuvant Corixa	Lymphocytic choriomeningitis virus vaccine
leishmaniasis vaccine Corixa	lymphoma vaccine – Biomira, Genitope
lenercept Hoffman La-Roche	LYP18
Lenograstim - Aventis, Chugai	lys plasminogen, recombinant
lepirudin Aventis	Lysosomal storage disease gene therapy -
leptin - Amgen, IC Innovations	Avigen
Leptin gene therapy Chiron Corporation	lysostaphin Nutrition 21

M 23 -- Gruenenthal M1 monoclonal antibodies -- Acorda Therapeutics MA 16N7C2 - Corvas Intl. malaria vaccine -- GlaxoSmithKline. AdProTech, Antigenics, Apovia, Aventis Pasteur, Axis Genetics, Behringwerke, CDCP, Chiron Vaccines, Genzyme Transgenics, Hawaii, MedImmune, NIH, NYU. Oxxon, Roche/Saramane, Biotech Australia, Rx Tech Malaria vaccine CDC/NIIMALVAC-1 malaria vaccine.multicomponent mammaglobin -- Corixa mammastatin -- Biotherapeutics mannan-binding lectin -- Natlmmu mannan-MUC1 -- Psiron MAP 30 Marinovir -- Phytera MARstem -- Maret MB-015 -- Mochida MBP -- ImmuLogic MCI-028 -- Mitsubishi-Tokyo MCIF -- Human Genome Sciences MDC -- Advanced BioScience -- Akzo Nobel, ICOS MDX 11 -- Medarex MDX 210 -- Medarex MDX 22 -- Medarex MDX 22 MDX 240 - Medarex MDX 33 MDX 44 -- Medarex MDX 447 -- Medarex MDX H210 -- Medarex MDX RA -- Houston BioTech., Medarex ME-104 -- Pharmexa Measles vaccine Mecasermin -- Cephalon/Chiron, Chiron MEDI 488 -- Medimmune MEDI 500

MEDI 507 -- BioTransplant melanin concentrating hormone --Neurocrine Biosciences melanocortins -- OMRF Melanoma monoclonal antibodies -- Viragen melanoma vaccine - GlaxoSmithKline, Akzo Nobel, Avant, Aventis Pasteur, Bavarian Nordic, Biovector, CancerVax, Genzyme Molecular Oncology, Humbolt, ImClone Systems, Memorial, NYU, Oxxon Melanoma vaccine Magevac -- Therion memory enhancers -- Scios meningococcal B vaccine -- Chiron meningococcal vaccine -- CAMR Meningococcal vaccine group B conjugate - North American Vaccine Meningococcal vaccine group B recombinant -- BioChem Vaccines. Microscience Meningococcal vaccine group Y conjugate -- North American Vaccine Meningococcal vaccine groups A B and C conjugate -- North American Vaccine Mepolizumab - GlaxoSmithKline Metastatin - EntreMed, Takeda Met-CkB7 -- Human Genome Sciences met-enkephalin -- TNI METH-1 -- Human Genome Sciences methioninase -- AntiCancer Methionine lyase gene therapy --AntiCancer Met-RANTES - Genexa Biomedical. Serono Metreleptin Microtubule inhibitor MAb Immunogen/Abgenix MGDF -- Kirin MGV -- Progenics micrin -- Endocrine microplasmin -- ThromboGenics

MIF -- Genetics Institute

MAb 45-2D9- - haematoporphyrin migration inhibitory factor - NIH conjugate Mim CD4.1 – Xycte Therapies mirostipen -- Human Genome Sciences MAb 4B4 Mitumomab (BEC-2) - ImClone Systems. MAb 4E3-CPA conjugate -- BCM Oncologia MAh 4E3-daunorubicin conjugate Merck KGaA MAb 50-6 MK 852 -- Merck MAb 50-61A - Institut Pasteur MLN 1202 (Anti-CCR2 monoclonal antibody) - Millenium Pharmaceuticals MAb 5A8 - Biogen MAb 791T/36-methotrexate conjugate Mohenakin -- NIS molgramostim -- Genetics Institute, Novartis MAb 7c11.e8 monoclonal antibodies -- Abgenix/Celltech, MAb 7E11 C5-selenocystamine conjugate MAb 93KA9 -- Novartis Immusol/ Medarex, Viragen/ Roslin Institute, Cambridge Antibody Tech./Elan MAb A5B7-cisplatin conjugate --Biodynamics Research, Pharmacia MAb 108 -MAb A5B7-I-131 MAb 10D5 --MAb 14.18-interleukin-2 immunocytokine -- MAb A7 MAh A717 -- Exocell Lexiden MAb A7-zinostatin conjugate MAb 14G2a -MAb ABX-RB2 - Abgenix MAh 15A10 -MAh ACA 11 MAb 170 -- Biomira MAb AFP-I-131 - Immunomedics MAb 177Lu CC49 --MAb AP1 MAb 17F9 MAb AZ1 MAb 1D7 MAb B3-LysPE40 conjugate MAb 1F7 - Immune Network MAb B4 - United Biomedical MAb 1H10-doxorubicin conjugate MAb B43 Genistein-conjugate MAb 26-2F MAb B43.13-Tc-99m -- Biomira MAb 2A11 MAb B43-PAP conjugate MAb 2E1 -- RW Johnson MAb B4G7-gelonin conjugate MAb 2F5 MAb BCM 43-daunorubicin conjugate --MAb 31.1 -- International Biolmmune BCM Oncologia Systems MAb 32 -- Cambridge Antibody Tech., MAb BIS-1 MAb BMS 181170 -- Bristol-Myers Squibb Pentech MAb 323A3 -- Centocor MAb BR55-2 MAb BW494 MAb 3C5 MAb C 242-DM1 conjugate -- ImmunoGen MAb 3F12 MAb C242-PE conjugate MAb 3F8 MAb c30-6 MAh 42/6 MAb CA208-cytorhodin-S conjugate --MAb 425 - Merck KGaA Hoechst Japan MAb 447-52D -- Merck Sharp & Dohme MAb CC49 -- Enzon

#### WO 2004/033651

MAh LiCO 16-88

# 50/498

MAb LL2-I-131 - Immunomedics MAb ch14.18 -MAb LL2-Y-90 MAb CH14.18-GM-CSF fusion protein --MAb LS2D617 -- Hybritech Lexiaen MAb LYM-1-gelonin conjugate MAb chCE7 MAb LYM-1-I-131 MAb CI-137 -- AMRAD MAb LYM-1-Y-90 MAb cisplatin conjugate MAb LYM-2 -- Peregrine MAb CLB-CD19 MAb M195 MAb CLB-CD19v MAb M195-bismuth 213 conjugate --MAb CLL-1 -- Peregrine Protein Design Labs MAb CLL-1-GM-CSF conjugate MAb CLL-1-IL-2 conjugate -- Peregrine MAb M195-gelonin conjugate MAb CLN IgG -- doxorubicin conjugates MAb M195-I-131 MAb M195-Y-90 MAb conjugates - Tanox MAb MA 33H1 - Sanofi MAb D612 MAb MAD11 MAb Dal B02 MAb MGb2 MAb DC101 -- ImClone MAb MINT5 MAb EA 1 -MAb MK2-23 MAb EC708 -- Biovation MAb MOC31 ETA(252-613) conjugate MAb EP-5C7 -- Protein Design Labs MAh MOC-31-In-111 MAb ERIC-1 -- ICRT MAb MOC-31-PE conjugate MAb F105 gene therapy MAb MR6 -MAb FC 2.15 MAh MRK-16 -- Aventis Pasteur MAh G250 -- Centocor MAh MS11G6 MAb GA6 MAb MX-DTPA BrE-3 MAh GA733 MAb MY9 MAh Gliomah-H -- Viventia Biotech MAb Nd2 -- Tosoh MAb HB2-saporin conjugate MAb NG-1 -- Hygeia MAb HD 37 -MAb NM01 - Nissin Food MAh HD37-ricin chain-A conjugate MAh HNK20 -- Acambis MAb OC 125 MAb OC 125-CMA conjugate MAb huN901-DM1 conjugate --MAb OKI-1 -- Ortho-McNeil ImmunoGen MAb OX52 -- Bioproducts for Science MAb I-131 CC49 -- Corixa MAb PMA5 MAb ICO25 MAb ICR12-CPG2 conjugate MAb PR1 MAb prost 30 MAb ICR-62 MAb IRac-ricin A conjugate MAh R-24 MAb R-24 α Human GD3 - Celltech MAh K1 MAb RFB4-ricin chain A conjugate MAb KS1-4-methotrexate conjugate MAb RFT5-ricin chain A conjugate MAb L6 -- Bristol-Myers Squibb, Oncogen MAb SC 1

MAb SM-3 ICRT	Muc-1 vaccine Corixa
MAb SMART 1D10 Protein Design Labs	mucosal tolerance Aberdeen
MAb SMART ABL 364 Novartis	mullerian inhibiting subst
MAb SN6f	muplestim - Genetics Institute, Novartis,
MAb SN6f-deglycosylated ricin A chain	DSM Anti-Infectives
conjugate -	murine MAb KS Biomedix
MAb SN6j	Mutant somatropin JCR Pharmaceutical
MAb SN7-ricin chain A conjugate	MV 833 Toagosei
MAb T101-Y-90 conjugate Hybritech	Mycoplasma pulmonis vaccine
MAb T-88 Chiron	Mycoprex XOMA
MAb TB94 Cancer ImmunoBiology	myeloperoxidase Henogen
MAb TEC 11	myostatin Genetics Institute
MAb TES-23 Chugai	Nacolomab tafenatox Pharmacia
MAb TM31 Avant	Nagrecor Scios
MAb TNT-1 Cambridge Antibody Tech.,	nagrestipen British Biotech
Peregrine	NAP-5 – Corvas Intl.
MAb TNT-3	NAPc2 – Corvas Intl.
MAb TNT-3 IL2 fusion protein -	nartograstim Kyowa
MAb TP3-At-211	Natalizumab Protein Design Labs
MAb TP3-PAP conjugate –	Nateplase – NIH, Nihon Schering
MAb UJ13A ICRT	nateplase Schering AG
MAb UN3	NBI-3001 Neurocrine Biosci.
MAb ZME-018-gelonin conjugate	NBI-5788 Neurocrine Biosci.
MAb-BC2 GlaxoSmithKline	NBI-6024 Neurocrine Biosci.
MAb-DM1 conjugate ImmunoGen	Nef inhibitors BRI
MAb-ricin-chain-A conjugate XOMA	Neisseria gonorrhoea vaccine Antex
MAb-temoporfin conjugates	Biologics
Monopharm C Viventia Biotech	Neomycin B-arginine conjugate
monteplase Eisai	Nerelimomab Chiron
montirelin hydrate Gruenenthal	Nerve growth factor – Amgen – Chiron,
moroctocog alfa Genetics Institute	Genentech
Moroctocog-alfa Pharmacia	Nerve growth factor gene therapy
MP 4	nesiritide citrate Scios
MP-121 Biopharm	neuregulin-2 CeNeS
MP-52 Biopharm	neurocan NYU
MRA Chugai	neuronal delivery system CAMR
MS 28168 Mitsui Chemicals, Nihon	Neurophil inhibitory Factor Corvas
Schering	Neuroprotective vaccine University of
MSH fusion toxin Ligand	Auckland
MSI-99 Genaera	neurotrophic chimaeras Regeneron
MT 201 Micromet	neurotrophic factor - NsGene, CereMedix

NeuroVax -- Immune Response neurturin -- Genentech neutral endopeptidase -- Genentech NGF enhancers -- NeuroSearch NHL vaccine -- Large Scale Biology NIP45 -- Boston Life Sciences NKI-B20 NM 01 - Nissin Food NMI-139 -- NitroMed NMMP -- Genetics Institute NN-2211 -- Novo Nordisk Noggin -- Regeneron Nonacog alfa Norelin -- Biostar Norwalk virus vaccine NRLU 10 -- NeoRx NRLU 10 PE -- NeoRx NT-3 -- Regeneron NT-4/5 -- Genentech NU 3056 NU 3076 NX 1838 -- Gilead Sciences NY ESO-1/CAG-3 antigen -- NIH NYVAC-7 -- Aventis Pasteur NZ-1002 -- Novazyme obesity therapy -- Nobex OC 10426 -- Ontogen OC 144093 -- Ontogen OCIF -- Sankvo Oct-43 -- Otsuka Odulimomab -- Immunotech OK PSA - liposomal OKT3-gamma-1-ala-ala OM 991 OM 992 Omalizumab -- Genentech oncoimmunin-L -- NIH Oncolysin B -- ImmunoGen Oncolvsin CD6 -- ImmunoGen Oncolysin M -- ImmunoGen Oncolysin S -- ImmunoGen

Oncophage -- Antigenics Oncostatin M -- Bristol-Myers Squibb OncoVax-CL -- Jenner Biotherapies OncoVax-P -- Jenner Biotherapies onercept -- Yeda onychomycosis vaccine -- Boehringer Ingelheim opebecan -- XOMA opioids -- Arizona Oprelvekin - Genetics Institute Oregovomab -- AltaRex Org-33408 b-- Akzo Nobel Orolip DP -- EpiCept orvzacystatin OSA peptides - GenSci Regeneration osteoblast-cadherin GF -- Pharis Osteocalcin-thymidine kinase gene therapy osteogenic protein -- Curis osteopontin -- OraPharma osteoporosis peptides - Integra, Telios osteoprotegerin - Amgen, SnowBrand otitis media vaccines -- Antex Biologics ovarian cancer - University of Alabama OX40-IgG fusion protein -- Cantab, Xenova P 246 -- Diatide P 30 -- Alfacell p1025 -- Active Biotech P-113<sup>^</sup> -- Demegen P-16 peptide -- Transition Therapeutics p43 -- Ramot P-50 peptide -- Transition Therapeutics p53 + RAS vaccine -- NIH, NCI PACAP(1-27) analogue paediatric vaccines -- Chiron Pafase -- ICOS PAGE-4 plasmid DNA -- IDEC PAI-2 - Biotech Australia. Human Therapeutics Palifermin (keratinocyte growth factor) --Amaen Palivizumab -- Medimmune

### **FIG. 28V**

PAM 4 -- Merck namiteplase -- Yamanouchi pancreatin, Minitabs -- Eurand Pangen -- Fournier Pantarin - Selective Genetics Parainfluenza virus vaccine - Pharmacia, Pierre Fahre paraoxanase -- Esperion parathyroid hormone - Abiogen, Korea Green Cross Parathyroid hormone (1-34) --Chugai/Suntory Parkinson's disease gene therapy -- Cell Genesys/ Ceregene Parvovirus vaccine -- MedImmune PCP-Scan - Immunomedics PDGF -- Chiron PDGF cocktail -- Theratechnologies peanut allergy therapy - Dynavax PEG anti-ICAM MAb - Boehringer Ingelheim PEG asparaginase -- Enzon PEG alucocerebrosidase PEG hirudin - Knoll PEG interferon-alpha-2a -- Roche PEG interferon-alpha-2b + ribavirin -Biogen, Enzon, ICN Pharmaceuticals, Schering-Plough PEG MAb A5B7 -Pegacaristim - Amgen -- Kirin Brewery --ZvmoGenetics Pegaldesleukin -- Research Corp pegaspargase -- Enzon pegfilgrastim -- Amgen PEG-interferon Alpha -- Viragen PEG-interferon Alpha 2A -- Hoffman La-Roche PEG-interferon Alpha 2B -- Schering-Plough PEG-r-hirudin -- Abbott PEG-rHuMGDF -- Amgen

PEG-uricase -- Mountain View Pegvisomant - Genentech PEGylated proteins, PolyMASC -- Valentis PEGylated recombinant native human leptin -- Roche Pemtumomab Penetratin -- Cyclacel Pepscan - Antisoma peptide G - Peptech, ICRT peptide vaccine - NIH ,NCI Pexelizumab pexiganan acetate -- Genaera Pharmaprojects No. 3179 -- NYU Pharmaprojects No. 3390 -- Ernest Orlando Pharmaprojects No. 3417 -- Sumitomo Pharmaprojects No. 3777 -- Acambis Pharmaprojects No. 4209 -- XOMA Pharmaprojects No. 4349 - Baxter Intl. Pharmaprojects No. 4651 Pharmaprojects No. 4915 -- Avanir Pharmaprojects No. 5156 -- Rhizogenics Pharmaprojects No. 5200 -- Pfizer Pharmaprojects No. 5215 -- Origene Pharmaprojects No. 5216 -- Origene Pharmaprojects No. 5218 -- Origene Pharmaprojects No. 5267 - ML Laboratories Pharmaprojects No. 5373 -- MorphoSvs Pharmaprojects No. 5493 -- Metabolex Pharmaprojects No. 5707 -- Genentech Pharmaprojects No. 5728 -- Autogen Pharmaprojects No. 5733 -- BioMarin Pharmaprojects No. 5757 -- NIH Pharmaprojects No. 5765 -- Gryphon Pharmaprojects No. 5830 -- AntiCancer Pharmaprojects No. 5839 -- Dyax Pharmaprojects No. 5849 -- Johnson & Johnson Pharmaprojects No. 5860 -- Mitsubishi-

Tokvo

Pharmaprojects No. 5869 - Oxford **GlycoSciences** Pharmaprojects No. 5883 -- Asahi Brewery Pharmaprojects No. 5947 -- StressGen Pharmaprojects No. 5961 --Theratechnologies Pharmaprojects No. 5962 -- NIH Pharmaprojects No. 5966 -- NIH Pharmaprojects No. 5994 -- Pharming Pharmaprojects No. 5995 - Pharming Pharmaprojects No. 6023 -- IMMUCON Pharmaprojects No. 6063 -- Cytoclonal Pharmaprojects No. 6073 -- SIDDCO Pharmaprojects No. 6115 -- Genzyme Pharmaprojects No. 6227 -- NIH Pharmaprojects No. 6230 -- NIH Pharmaprojects No. 6236 -- NIH Pharmaprojects No. 6243 -- NIH Pharmaprojects No. 6244 -- NIH Pharmaprojects No. 6281 -- Senetek Pharmaprojects No. 6365 -- NIH Pharmaprojects No. 6368 -- NIH Pharmaprojects No. 6373 -- NIH Pharmaprojects No. 6408 - Pan Pacific Pharmaprojects No. 6410 - Athersys Pharmaprojects No. 6421 - Oxford GlycoSciences Pharmaprojects No. 6522 -- Maxvoen Pharmaprojects No. 6523 -- Pharis Pharmaprojects No. 6538 -- Maxygen Pharmaprojects No. 6554 -- APALEXO Pharmaprojects No. 6560 -- Ardana Pharmaprojects No. 6562 -- Baver Pharmaprojects No. 6569 -- Eos Phenoxazine Phenylase -- Ibex Pigment epithelium derived factor plasminogen activator inhibitor-1, recombinant -- DuPont Pharmaceuticals

Plasminogen activators - Abbott Laboratories, American Home Products, Boehringer Mannheim, Chiron Corporation, DuPont Pharmaceuticals, Eli Lilly, Shionogi, Genentech, Genetics Institute, GlaxoSmithKline, Hemispherx Biopharma, Merck & Co, Novartis, Pharmacia Corporation, Wakamoto, Yeda plasminogen-related peptides -- Bio-Tech. General/MGH platelet factor 4 -- RepliGen Platelet-derived growth factor - Amgen --ZvmoGenetics plusonermin- Havashibara PMD-2850 -- Protherics Pneumococcal vaccine -- Antex Biologics, Aventis Pasteur Pneumococcal vaccine intranasal --BioChem Vaccines/Biovector PR1A3 PR-39 pralmorelin -- Kaken Pretarget-Lymphoma -- NeoRx Priliximab -- Centocor PRO 140 -- Progenics PRO 2000 -- Procept PRO 367 -- Progenics PRO 542 -- Progenics pro-Apo A-I -- Esperion prolactin -- Genzyme Prosaptide TX14(A) -- Bio-Tech. General prostate cancer antbodies - Immunex, UroCor prostate cancer antibody therapy --Genentech/UroGenesys, Genotherapeutics prostate cancer immunotherapeutics -- The PSMA Development Company prostate cancer vaccine -- Aventis Pasteur,

Zonagen, Corixa, Dendreon, Jenner Biotherapies, Therion Biologics

prostate-specific antigen -- EntreMed RD 62198 rDnase -- Genentech protein A -- RepliGen RDP-58 -- SangStat protein adhesives -- Enzon RecepTox-Fce -- Kervx protein C - Baxter Intl., PPL Therapeutics, RecepTox-GnRH - Keryx, MTR ZvmoGenetics protein C activator - Gilead Sciences Technologies RecepTox-MBP - Keryx, MTR protein kinase R antags -- NIH Technologies protirelin -- Takeda recFSH -- Akzo Nobel, Organon protocadherin 2 -- Caprion Pro-urokinase - Abbott, Bristol-Myers REGA 3G12 Regavirumab -- Teijin Squibb, Dainippon, Tosoh -- Welfide P-selectin glycoprotein ligand-1 -- Genetics relaxin -- Connetics Corp Renal cancer vaccine -- Macropharm Institute repifermin -- Human Genome Sciences pseudomonal infections -- InterMune Respiratory syncytial virus PFP-2 vaccine --Pseudomonas vaccine -- Cytovax Wveth-Lederle PSGL-Ig -- American Home Products Respiratory syncytial virus vaccine -PSP-94 - Procvon GlaxoSmithKline, Pharmacia, Pierre Fabre PTH 1-34 -- Nobex Respiratory syncytial virus vaccine Quilimmune-M -- Antigenics inactivated R 744 - Roche Respiratory syncytial virus-parainfluenza R 101933 virus vaccine -- Aventis Pasteur, R 125224 -- Sankvo Pharmacia RA therapy -- Cardion Rabies vaccine recombinant -- Aventis Reteplase -- Boehringer Mannheim, Hoffman La-Roche Pasteur, BioChem Vaccines, Kaketsuken Retropep -- Retroscreen Pharmaceuticals 3 4 1 RFB4 (dsFv) PE38 RadioTheraCIM -- YM BioSciences RFI 641 -- American Home Products Ramot project No. 1315 -- Ramot RFTS -- UAB Research Foundation Ramot project No. K-734A -- Ramot RG 12986 -- Aventis Pasteur Ramot project No. K-734B -- Ramot RG 83852 -- Aventis Pasteur Ranibizumab (Anti-VEGF fragment) --RG-1059 -- RepliGen Genentech rGCR -- NIH RANK -- Immunex rGLP-1 -- Restoragen rannirnase -- Alfacell ranpirnase-anti-CD22 MAb -- Alfacell rGRF -- Restoragen rh Insulin - Eli Lilly RANTES inhibitor -- Milan RHAMM targeting peptides - Cangene RAPID drug delivery systems -- ARIAD rHb1.1 - Baxter Intl. rasburicase -- Sanofi rhCC10 -- Claragen rBPI-21, topical -- XOMA rhCG -- Serono RC 529 -- Corixa Rheumatoid arthritis gene therapy rCFTR -- Genzyme Transgenics

SB RA 31012 -Rheumatoid arthritis vaccine -- Veterans SC 56929 -- Pharmacia Affairs Medical Center SCA binding proteins - Curis, Enzon rhl H -- Serono scFv(14E1)-ETA Berlex Laboratories. Ribozyme gene therapy -- Genset Schering AG Rickettsial vaccine recombinant ScFv(FRP5)-ETA -RIGScan CR - Neoprobe ScFv6C6-PE40 -RIP-3 -- Rigel SCH 55700 - Celltech Rituximab -- Genentech Schistosomiasis vaccine -- Glaxo RK-0202 -- RxKinetix Wellcome/Medeva, Brazil RLT peptide -- Esperion SCPF -- Advanced Tissue Sciences rM/NFI -- IVAX scuPA-suPAR complex - Hadasit rmCRP -- Immtech SD-9427 -- Pharmacia RN-1001 -- Renovo SDF-1 -- Ono RN-3 -- Renovo SDZ 215918 -- Novartis RNAse conjugate -- Immunomedics SDZ 280125 -- Novartis RO 631908 - Roche SDZ 89104 - Novartis Rotavirus vaccine -- Merck SDZ ABL 364 -- Novartis RP 431 -- DuPont Pharmaceuticals SDZ MMA 383 -- Novartis RP-128 -- Resolution Secretin - Ferring, Repligen RPE65 gene therapy serine protease inhibs -- Pharis RPR 110173 -- Aventis Pasteur sermorelin acetate - Serono RPR 115135 -- Aventis Pasteur SFRP-1 -- Viron RPR 116258A -- Aventis Pasteur sertenef -- Dainippon rPSGL-Ig -- American Home Products serum albumin, Recombinant human -r-SPC surfactant -- Byk Gulden Aventis Behring RSV antibody -- Medimmune serum-derived factor -- Hadasit Ruplizumab -- Biogen Sevirumab -- Novartis rV-HER-2/neu -- Therion Biologics SGN 14 - Seatle Genetics SA 1042 -- Sankyo SGN 15 -- Seatle Genetics sacrosidase - Orphan Medical SGN 17/19 -- Seatle Genetics Sant 7 SGN 30 - Seatle Genetics Sargramostim -- Immunex SGN-10 -- Seatle Genetics saruplase - Gruenenthal SGN-11 -- Seatle Genetics Satumomab -- Cytogen SH 306 -- DuPont Pharmaceuticals SB 1 -- COR Therapeutics Shanvac-B -- Shantha SB 207448 -- GlaxoSmithKline Shigella flexneri vaccine - Avant, Acambis, SB 208651 - GlaxoSmithKline Novavax SB 240683 - GlaxoSmithKline Shigella sonnei vaccine --SB 249415 -- GlaxoSmithKline

SB 249417 -- GlaxoSmithKline

SB 6 -- COR Therapeutics

sICAM-1 -- Boehringer Ingelheim

Silteplase -- Genzyme

SIV vaccine - Endocon, Institut Pasteur SK 896 -- Sanwa Kagaku Kenkyusho SK-827 -- Sanwa Kagaku Kenkyusho Skeletex -- CellFactors SKF 106160 -- GlaxoSmithKline S-nitroso-AR545C -SNTP -- Active Biotech somatomedin-1 - GroPep, Mitsubishi-Tokyo, NIH somatomedin-1 carrier protein -- Insmed somatostatin -- Ferring Somatotropin/ Human Growth Hormone -- Bio-Tech. General, Eli Lilly somatropin - Bio-Tech. General, Alkermes. SUIS-LHRH -- United Biomedical ProLease, Aventis Behring, Biovector, Cangene, Dong-A, Eli Lilly, Emisphere, Enact, Genentech, Genzyme Transgenics. YM BioSciences Novartis, Novo Nordisk, Pharmacia Serono, TranXenoGen somatropin derivative -- Schering AG somatropin, AIR -- Eli Lilly Somatropin, inhaled -- Eli Lilly/Alkermes somatropin, Kabi -- Pharmacia somatropin, Orasome -- Novo Nordisk Sonermin -- Dainippon Pharmaceutical SP(V5.2)C - Supertek SPf66 sphingomyelinase -- Genzyme SR 29001 - Sanofi SR 41476 -- Sanofi SR-29001 -- Sanofi SS1(dsFV)-PE38 -- NeoPharm ß2 microglobulin -- Avidex ß2-microglobulin fusion proteins -- NIH ß-amyloid peptides -- CeNeS ß-defensin -- Pharis Staphylococcus aureus infections --Inhibitex/ZLB

Staphylococcus aureus vaccine conjugate --Nabi Staphylococcus therapy -- Tripep Staphylokinase - Biovation, Prothera, Thrombogenetics Streptococcal A vaccine -- M6 Pharmaceuticals. North American Vaccine Streptococcal B vaccine -- Microscience Streptococcal B vaccine recombinant --Biochem Vaccines Streptococcus pyogenes vaccine STRL-33 -- NIH Subalin -- SRC VB VECTOR SUIS -- United Biomedical SUN-E3001 -- Suntory super high affinity monoclonal antibodies -Grandis/InfiMed, CSL, InfiMed, MacroMed, Superoxide dismutase - Chiron, Enzon, Ube Industries, Bio-Tech, Yeda superoxide dismutase-2 -- OXIS suppressin - UAB Research Foundation SY-161-P5 -- ThromboGenics SY-162 -- ThromboGenics Systemic lupus erythematosus vaccine --MedClone/VivoRx T cell receptor peptides -- Xoma T cell receptor peptide vaccine T4N5 liposomes -- AGI Dermatics TACI, soluble -- ZymoGenetics targeted apoptosis -- Antisoma tasonermin -- Boehringer Ingelheim TASP TASP-V Tat peptide analogues -- NIH TBP I -- Yeda TBP II TRV25H -- NIH Tc 99m ior cea1 -- Center of Molecular **Immunology** 

Tc 99m P 748 -- Diatide

TIF -- Xoma

Tifacogin - Chiron, NIS, Pharmacia

### 58/498

Tissue factor -- Genentech Tc 99m votumumab -- Intracell Tissue factor pathway inhibitor Tc-99m rh-Annexin V - Theseus Imaging T.IN-135 -- Tsumura teceleukin - Biogen TM 27 -- Avant tenecteplase -- Genentech TM 29 -- Avant Teriparatide -- Armour Pharmaceuticals, TMC-151 - Tanabe Seiyaku Asahi Kasei, Eli Lilly TNF tumour necrosis factor -- Asahi Kasei terlipressin -- Ferring TNF Alpha -- Cytlmmune testisin -- AMRAD TNF antibody -- Johnson & Johnson Tetrafibricin -- Roche TNF binding protein -- Amgen TFPI -- EntreMed TNF degradation product -- Oncotech taD-IL-2 -- Takeda TNF receptor -- Immunex TGF-Alpha -- ZymoGenetics TNF receptor 1, soluble -- Amgen TGF-ß -- Kolon TNF Tumour necrosis factor-alpha -- Asahi TGF-R2 -- Insmed Kasei, Genetech, Mochida TGF-ß3 -- OSI TNF-Alpha inhibitor -- Tripep Thalassaemia gene therapy -- Crucell TNFR:Fc gene therapy - Targeted Genetics TheraCIM-h-R3 -- Center of Molecular TNF-SAM2 Immunology, YM BioSciences ToleriMab -- Innogenetics Theradigm-HBV -- Epimmune Toxoplasma gondii vaccine --Theradigm-HPV -- Epimmune GlaxoSmithKline Theradigm-malaria -- Epimmune TP 9201 - Telios Theradigm-melanoma -- Epimmune TP10 -- Avant TheraFab - Antisoma TP20 -- Avant ThGRF 1-29 -- Theratechnologies ThGRF 1-44 -- Theratechnologies tPA -- Centocor trafermin -- Scios Thrombin receptor activating peptide --TRAIL/Apo2L -- Immunex Abbott TRAIL-R1 MAb - Cambridge Antibody thrombomodulin - Iowa, Novocastra Thrombopoietin -- Dragon Pharmaceuticals, Technologies transferrin-binding proteins -- CAMR Genentech Transforming growth factor-beta-1 -thrombopoietin, Pliva -- Receptron Genentech Thrombospondin 2 transport protein -- Genesis thrombostatin -- Thromgen Trastuzumab -- Genetech thymalfasin -- SciClone TRH -- Ferring thymocartin – Gedeon Richter Triabin -- Schering AG thymosin Alpha1 -- NIH thyroid stimulating hormone -- Genzyme Triconal Triflavin tICAM-1 -- Bayer troponin I -- Boston Life Sciences Tick anticoagulant peptide -- Merck TRP-2" -- NIH

FIG. 28BB

trypsin inhibitor -- Mochida

WO 2004/033651 PCT/US2003/031974

59/498

Vascular endothelial growth factors - R&D TSP-1 gene therapy -Systems TT-232 vascular targeting agents -- Peregrine TTS-CD2 -- Active Biotech vasopermeation enhancement agents --Tuberculosis vaccine -- Aventis Pasteur. Peregrine Genesis Tumor Targeted Superantigens -- Active vasostatin -- NIH Biotech -- Pharmacia VCI -- Bio-Tech, General VEGF - Genentech. Scios tumour vaccines -- PhotoCure tumour-activated prodrug antibody VEGF inhibitor -- Chugai VEGF-2 -- Human Genome Sciences conjugates -- Millennium/ImmunoGen VEGF-Trap -- Regeneron tumstatin -- ILEX viscumin, recombinant -- Madaus Tuvirumab -- Novartis Vitaxin TV-4710 - Teva Vitrase - ISTA Pharmaceuticals TWEAK receptor -- Immunex West Nile virus vaccine -- Bavarian Nordic TXU-PAP WP 652 TY-10721 - TOA Eiyo Type I diabetes vaccine -- Research Corp WT1 vaccine -- Corixa WX-293 -- Wilex BioTech. Typhoid vaccine CVD 908 WX-360 -- Wilex BioTech. U 143677 -- Pharmacia WX-LIK1 -- Wilex BioTech. U 81749 -- Pharmacia XMP-500 - XOMA UA 1248 -- Arizona XomaZvme-791 -- XOMA UGIF -- Sheffield XTL 001 -- XTL Biopharmaceuticals UIC 2 XTL 002 -- XTL Biopharmaceuticals UK 101 veast delivery system -- Globelmmune UK-279276 - Corvas Intl. Yersinia pestis vaccine urodilatin -- Pharis YIGSR-Stealth -- Johnson & Johnson urofollitrophin -- Serono Yissum Project No. D-0460 -- Yissum Urokinase -- Abbott YM 207 - Yamanouchi uteroferrin-- Pepgen YM 337 -- Protein Design Labs V 20 -- GLYCODesign Yttrium-90 labelled biotin V2 vasopressin receptor gene therapy Yttrium-90-labeled anti-CEA MAb T84.66 vaccines -- Active Biotech 7D 0490 - AstraZeneca Varicella zoster glycoprotein vaccine -Research Corporation Technologies ziconotide -- Elan Varicella zoster virus vaccine live -- Cantab ZK 157138 -- Berlex Laboratories Pharmaceuticals Zolimomab aritox Vascular endothelial growth factor -Zorcell -- Immune Response

Genentech, University of California

ZRXL peptides - Novartis